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Abstract
This document is an update of Guidelines published in 2005 and now includes scientiﬁc publications through to May 2010. It provides
evidence-based recommendations for the most common management questions occurring in routine clinical practice in the management
of adult patients with LRTI. Topics include management outside hospital, management inside hospital (including community-acquired
pneumonia (CAP), acute exacerbations of COPD (AECOPD), acute exacerbations of bronchiectasis) and prevention. Background sec-
tions and graded evidence tables are also included. The target audience for the Guideline is thus all those whose routine practice
includes the management of adult LRTI.
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Introduction
In 2005 the European Respiratory Society (ERS), in collabora-
tion with The European Society for Clinical Microbiology and
Infectious Diseases (ESCMID), published guidelines on the
management of lower respiratory tract infections (LRTI) in
adults [1]. This document was based on published scientiﬁc lit-
erature up to the end of 2002. We have now updated these
guidelines to include publications to May 2010. The Taskforce
responsible for guideline development has been sponsored by
the ERS and ESCMID. Members of the Taskforce are members
of the sponsoring ERS and/or ESCMID.
Our objective is to provide evidence-based recommenda-
tions for the most common management questions occurring
in routine clinical practice in the management of adult
patients with LRTI. The target audience for the guidelines is
thus all those whose routine practice includes the manage-
ment of adult LRTI.
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This document begins with deﬁnitions and background sec-
tions on microbial cause, resistance and pharmacokinetics/phar-
macodynamics, with conventional referencing. The guideline
section captures management outside hospital, management
inside hospital (including community-acquired pneumonia
(CAP), acute exacerbations of chronic obstructive pulmonary
disease (AECOPD) and acute exacerbations of bronchiectasis)
and prevention. The guidelines are about the management of
infection. This means that for conditions such as AECOPD,
aspects of management that are unreleated to infection (e.g. use
of steroids or bronchodilators) are not included. It contains the
graded recommendations but also the background information
for each recommendation, with details about each new cited
reference and the evidence grades. Because this is an update,
original data and publications have usually not been repeated
and the reader is referred to the original publication [1] for this.
As this is an update using the same methodologies, the layout of
the document, including text, recommendations and evidence
tables, is the same as in 2005.
Methods
Using the same search ﬁlter as for the 2005 document (this
is described in detail in the previous publication [1] and web-
site documents—http://www.ersnet.org; http://www.escmid.
org) we identiﬁed relevant manuscripts in PubMed published
from July 2002 to May 2010. Thereby we retrieved 15 261
titles and loaded them into an electronic database. From
these, 1677 titles were identiﬁed as potentially relevant pub-
lications by the expert panel members. The same process of
evidence appraisal and grading (Appendix 1) and recommen-
dation development and grading (Appendix 2) as in the 2005
document was used.
The document takes each clinical question for which there
was a recommendation in the 2005 guidelines and presents
new information when available, followed by a new recom-
mendation. In some circumstances, because of lack of new
evidence, or sometimes even in the presence of new evi-
dence, the recommendation is unchanged from 2005. Where
this is the case it is indicated.
In some parts of the guidelines new questions and recom-
mendations have been added to cover relevant areas not
included in the 2005 guidelines (e.g. aspiration pneumonia).
LRTI Deﬁnitions
The guidelines are to be used to guide the management of
adults with lower respiratory tract infection (LRTI). As will be
seen in the following text, this diagnosis, and the other clinical
syndromes within this grouping, can be difﬁcult to identify
accurately. In the absence of agreed deﬁnitions of these syn-
dromes, these guidelines are to be used when, in the opinion
of a clinician, an LRTI syndrome is present. The following are
put forward as deﬁnitions to guide the clinician, but it will be
seen in the ensuing text that some of these labels will always
be inaccurate. These deﬁnitions are pragmatic and based on a
synthesis of available studies. They are primarily meant to be
simple to apply in clinical practice, and this might be at the
expense of scientiﬁc accuracy. These deﬁnitions are not mutu-
ally exclusive, with lower respiratory tract infection being an
umbrella term that includes all others, which can also be used
for cases that cannot be classiﬁed into one of the other
groups. No new evidence has been identiﬁed that would lead
to a change in the clinical deﬁnitions, which are therefore
unchanged from the 2005 publication.
Since the publication of the 2005 guidelines the term
health care-associated pneumonia (HCAP) has been put for-
ward to capture groups of patients with pneumonia, some
acquired outside hospital, expected to be caused by similar
pathogens, but different from those usually found in com-
munity-acquired LRTI. In the opinion of the taskforce mem-
bers the evidence base does not support the use of this
term as being clinically relevant in Europe at the present
time. HCAP is therefore not covered further in this docu-
ment [2–17].
Lower respiratory tract infection
An acute illness (present for 21 days or less), usually with
cough as the main symptom, with at least one other lower
respiratory tract symptom (sputum production, dyspnoea,
wheeze or chest discomfort/pain) and no alternative explana-
tion (e.g. sinusitis or asthma).
Acute Bronchitis (AB)
An acute illness, occurring in a patient without chronic lung
disease, with symptoms including cough, which may or may
not be productive and associated with other symptoms or
clinical signs that suggest LRTI and no alternative explanation
(e.g. sinusitis or asthma).
Inﬂuenza
An acute illness, usually with fever, together with the presence
of one or more of headache, myalgia, cough or sore throat.
Suspected community-acquired pneumonia (CAP)
An acute illness with cough and at least one of new focal
chest signs, fever >4 days or dyspnoea/tachypnoea, and with-
out other obvious cause.
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Deﬁnite community-acquired pneumonia (CAP)
As above, but supported by chest radiograph ﬁndings of
lung shadowing that is likely to be new. In the elderly, the
presence of chest radiograph shadowing accompanied by
acute clinical illness (unspeciﬁed) without other obvious
cause.
Acute exacerbation of COPD (AECOPD)
An event in the natural course of the disease characterized
by a worsening of the patient’s baseline dyspnoea, cough
and/or sputum beyond day-to-day variability sufﬁcient to
warrant a change in management. If chest radiograph shad-
owing, consistent with infection, is present the patient is
considered to have CAP.
Acute exacerbation of bronchiectasis (AEBX)
In a patient with features suggestive of bronchiectasis, an
event in the natural course of the disease characterized by a
worsening in the patient’s baseline dyspnoea, and/or cough
and/or sputum beyond day-to-day variability sufﬁcient to
warrant a change in management. If chest radiograph shad-
owing, consistent with infection, is present the patient is
considered to have CAP.
Background
What new information is available about the microbiologi-
cal causes of LRTI?
Wide variations between studies regarding the frequency of
each microorganism can be explained by several factors,
including differences in studied populations (e.g. age range or
other risk factors), geographical area, studied samples and
microbiological methods; for example, some studies focused
on bacterial agents and others on viruses and intracellular
bacteria. Supplementing traditional diagnostic methods with
new technology-based methods could achieve higher micro-
bial yield [18].
1 In the majority of studies of LRTI there is a large propor-
tion of cases with no pathogen identiﬁed, either because
the appropriate tests were not performed (as is usually
the rule in outpatients) or the organism was missed. Age
>70 years, renal and cardiac co-morbid illnesses and non
alveolar inﬁltrates were independently associated with a
higher proportion of unknown aetiology in 204 patients
hospitalized for CAP [19].
2 On the other hand, multiple organisms may be found in
adults, as already described in youngsters. Paediatric
studies have found polymicrobial infections in CAP: dual
viral infection is present in 0–14%, dual bacterial infec-
tion in 0–14%, and mixed viral-bacterial infection in 3–
30% [20].
In hospitalized adult non-immunocompromised patients,
polymicrobial CAP occurred in 6–26% [21–28]. Gutierrez
et al. [21] report two or more pathogens at all ages, and
as well in inpatients and outpatients, the most frequent
combinations being those of bacteria with an atypical organ-
ism (29%) and two bacteria (29%); patients with mixed
pneumonia are likely to have more co-morbidities and a
more altered outcome. Angeles Marcos et al. [23] found
that the most frequent co-pathogens were S. pneumoniae
and C. pneumoniae, and the most frequent combinations
S. pneumoniae and either inﬂuenza or parainﬂuenza virus,
and inﬂuenza virus with C. pneumoniae. De Roux et al. [29]
reported that in the 10% of patients with mixed CAP,
S. pneumoniae was the most prevalent microorganism; the
most frequent combination was S. pneumoniae with H. inﬂu-
enzae; inﬂuenza virus A and S. pneumoniae was the most
frequent association in the mixed pyogenic pneumonia
group. Among the 17% of patients with mixed infections,
Song et al. found 73% of patients with two different patho-
gens, 13% with three different pathogens and 13% with four
different pathogens. The most frequent combination was
S. pneumoniae with C. pneumoniae (15%). Mixed infections
were found in 25% of patients with pneumococcal CAP
[28]. Jennings et al. [27] found that polymicrobial infections
involving bacterial and viral pathogens occurred in 15% of
patients with CAP and might be associated with severe
pneumonia. Johansson et al. found two or more pathogens
in 35% of patients with CAP with a determined aetiology,
most commonly S. pneumoniae together with a respiratory
virus [18]. Evidence of concurrent bacterial infection was
found in lung tissue specimens from 22 (29%) of the 77 US
patients with fatal cases of conﬁrmed 2009 pandemic inﬂu-
enza A (H1N1), including 13% caused by S. pneumoniae
[30].
Table 1 summarizes the microbiological aetiologies of
LRTI in the community. Studies have investigated the micro-
biological causes of CAP in outpatients (Table 2) and patients
admitted to hospital (Table 3) or to the intensive care unit
(Table 4). Most studies of mild infections suggest that micro-
bial aetiologies in outpatients are similar to those in hospital-
ized patients [31–57].
In the community and on the regular ward, extracellular
bacteria, especially Streptococcus pneumoniae (S. pneumoniae),
are in ﬁrst place, followed by Haemophilus inﬂuenzae
(H. inﬂuenzae), Staphylococcus aureus (S. aureus) and Moraxella
catarrhalis. Among intracellular bacilli, Mycoplasma pneumoniae
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(M. pneumoniae) is the most common, followed in frequency
by Legionella and Chlamydia species, with viruses being
involved in up to 60% of community-acquired LRTI and 30%
of CAP. In the intensive care unit, S. aureus, Gram-negative
bacilli and Legionella spp. might be more frequently encoun-
tered. Recurrence of CAP is more likely when Gram-nega-
tive bacteria are involved, and less likely if Legionella spp. are
involved [58].
Originally a nosocomial pathogen, methicillin-resistant
S. aureus (MRSA) disseminated during the last decade in the
community (community-acquired MRSA, CA-MRSA). Methi-
cillin resistance is mediated by the mecA gene that has
been associated with the Panton-Valentine leukocidin (PVL)
toxin, which creates lytic pores in the cell membranes of
neutrophils and induces the release of neutrophil chemotac-
tic factors that promote inﬂammation and tissue destruc-
tion. New PVL-positive clones may be arising and
disseminating in the community [59]. MRSA has emerged as
an infectious agent of increasing frequency associated with
skin and soft-tissue infections in the community setting. How-
ever, CA-MRSA can also lead to severe pulmonary infections,
including necrotizing and haemorrhagic pneumonia, pneumo-
thorax, pneumopyothorax, empyema, ventilatory failure and
septicaemia [60–63].
Coxiella burnetii, a Gram-negative intracellular bacterium,
and a potential bioterrorism agent, is responsible for Q
fever, which may have a wide variety of clinical manifesta-
tions, including ﬂu-like syndrome, pneumonia and long-lasting
fatigue syndrome. C. burnetii is present worldwide, cattle,
sheep and goats being the most common reservoirs. Q fever
occurs as endemic cases or as outbreaks in endemic areas.
Outbreaks have ocurred in Europe in recent decades includ-
ing Switzerland, Spain, the UK, Germany and most recently,
the Netherlands repeatedly since 2007, with more than 4000
notiﬁed cases [64].
The importance of viruses as causal agents has been con-
ﬁrmed in LRTI [65] and CAP [22,23,66]. In the majority of
aetiological CAP studies looking for viruses and bacteria,
TABLE 1. Aetiology of lower respiratory tract infection in the community (%). (Blank boxes indicate organism not sought)
Reference n SP HI MC SA MP CS CPne CB Virus Inﬂuenza
Boldy et al. [91] 42 3.0 3.0 3.0 0 8.0 0 0 21.0 10.0
Creer et al. 2006 [65] 80 18.8 6.3 1.2 1.2 61.3 23.8
Everett [92] 187 6.0 2.0 0 6.0 4.0
Fransen and Wolontis [93] 78 8.0 3.0 3.0 3.0 20.0 12.0
Graffelman et al. [94] 145 6.2 9.0 2.1 9.0 1.3 39.0 30.3
Holm et al. [95] 364 6 4 1 <1 3 <1 24 10
Hopstaken et al. [96] 247 2.9 13.8 2.9
Macfarlane et al. [97] 206 30.0 8.0 2 1.0 0.5 0.5 8.0 5.0
Macfarlane et al. [98] 316 17.1 9.8 2.2 7.3 17.4 19.3 7.3
Shaw and Fry [99] 40 16.0 14.0 10.0 5.0 3.0 0 11.0 11.0
Range 3–30 3–14 1–3 1–10 0.5–9 0–3 0–0.5 6–61 4–30
SP, Streptococcus pneumoniae; HI, Haemophilus inﬂuenzae; LP, Legionella pneumophila; MC, Moraxella catarrhalis; SA, Staphylococcus aureus; GNEB, Gram-negative bacilli; MP, Myco-
plasma pneumoniae; CS, Chlamydia species (all); CPne, Chlamydophila pneumoniae; CPsi, Chlamydophila psittaci; CB, Coxiella burnetii.
TABLE 2. Aetiology of community-acquired pneumonia in the community (%). (Blank boxes indicate organism not sought)
Reference n SP HI LP MC SA GNEB MP CS CPne CPsi CB Virus Inﬂuenza
Almirall et al. [100] 105 12.4 0 2.9 0 0 7.6 15.2 15.2 0 0 11.4 0
Almirall et al. [31] 232 11.6 0.4 2.2 0 0.4 3.9 9.5 0 2.2 14.2 8. 2
Beovic et al. [101] 109 13.8 3.6 1.8 2.7 0.9 24.8 21.1 0.9
Berntsson et al. [102] 54 9.3 11.1 0 – – 37.0 3.7 – 3.7 0 13.0 7.4
Blanquer et al. [103] 48 12.5 0 12.5 0 0 12.5 – – 0 0 20.8 14.6
BTS et al. [104] 67 6.0 0 0 0 0 0 3.0 28.0 10.0
Dulake and Selkon [105] 36 19.0 14.0 0 0 2.0 0 2 2
Foy et al. [106] 2256 12.0 20.0 25.0 8.0
Holm et al. [95] 48 15 4 0 0 2 0 8 0 13 4
Jokinen et al. [42] 304 41 4 3 10 12 10 1 9 2
Marrie et al. [49] 149 22.8 10.7 2.7 2.7
Marrie et al. [107] 507 5.9 4.9 15 12
Melbye et al. [108] 36 11.1 0 0 – – 13.9 8.3 0 – 33.3 19.4
Michetti et al. [52] 119 0 0 3.4 0 0 32.8 16.0 6.7 9.2 0 5.9 3.4
Miyashita et al. [109] 106 12.3 4.7 1.9 0.9 27.4 1.9
Wattanathum et al. [25] 98 13.3 1 8.2 29.6 36.7
Woodhead et al. [110] 236 36.0 10.0 0.5 0 1.0 1.0 1.0 1.0 0 13.0 8.0
Range 0–36 0–14 0–13 0–3 0–1 0–1 1–33 1–16 7–37 0–9 0–3 2–33 0–19
SP, Streptococcus pneumoniae; HI, Haemophilus inﬂuenzae; LP, Legionella pneumophila; MC, Moraxella catarrhalis; SA, Staphylococcus aureus; GNEB, Gram-negative enteric bacilli; MP,
Mycoplasma pneumoniae; CS, Chlamydia species (all); CPne, Chlamydophila pneumoniae; CPsi, Chlamydophila psittaci; CB, Coxiella burnetii.
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viruses are the most common aetiological agents after
S. pneumoniae [23,67].
Sporadic viral pneumonias that occurred in recent years
were due to new virus, avian inﬂuenza virus, hantavirus and
coronavirus. Avian inﬂuenza virus A/H5N1 infections
increase the risk of a pandemic, are much more severe than
routine seasonal inﬂuenza, and are associated with severe ill-
ness and a >50% mortality rate, especially in people aged
10–39 years [68,69]. The hantavirus pulmonary syndrome
was recognized in 1983, but was retrospectively identiﬁed
using serological testing in patients who had a similar illness
in 1959 [70]. The syndrome can result from several hantavi-
ruses, such as Sin Nombre virus. Avoidance of areas where
infected rodents live is the only preventive measure. An out-
break of severe acute respiratory syndrome (SARS) was
reported in 2002, mainly in Asian countries and Canada
[71,72]. New viruses belonging to the coronaviridae family
were found to be responsible.
In the spring of 2009, an outbreak of severe pneumonia
was reported in conjunction with the concurrent isolation of
TABLE 3. Aetiology of community-acquired pneumonia in adults admitted to hospital (%). (Blank boxes indicate organism not
sought)
Reference n SP HI LP SA MC GNEB PA MP CS CPne CPsi CB Virus Inﬂuenza
Angeles Marcos et al. [23] 198 29.3 5.1 3.0 2.5 0 2.0 1.0 1.5 0.5 0.5 0 1.0 23.2 8.1
Arancibia et al. [111] 559 13.8 5.0 5.2 10.7 7.0 1.8 9.5 7.7 0.2 1.6 2.8
Aubertin et al. [112] 274 12.4 3.3 10.6 2.2 0.0 2.9 8.8 – – 2.6 0.7 2.6 0.0
Ausina et al. [113] 207 39.1 1.0 6.3 0.5 0.0 2.9 16.9 – – 6.3 2.4 3.9 2.4
Berntsson et al. [114] 127 54.3 3.9 0.8 0.8 0.0 0.0 14.2 – – 2.4 0.0 18.1 12.6
Blanquer et al. [103] 462 14.7 1.9 13.9 1.7 0.0 3.2 3.5 – – 0.2 0.6 13.0 7.8
Blasi et al. [33] 207 7.7 2.4 4.8 3.9 1.0 5.3 8.2 10.1 10.1 0.0 0.0 – –
Bohte et al. [34] 334 26.9 7.8 2.4 1.2 1.5 3.3 5.7 – – – 0.3 8.1 4.2
BTS [104] 453 34.0 5.7 2.0 0.9 0.0 0.9 17.9 – – 2.9 1.1 7.1 7.1
Burman et al. [115] 196 32.1 4.6 2.0 1.5 1.5 1.0 8.7 – – 3.1 0.0 21.9 8.7
Charles et al. [116] 885 14 5 3 1 1 2 2 9 2 15 8
de Roux et al. [22] 338 41 14.5 10 12 18 12
Ewig et al. [19] 204 19 6 5 2 1 6.5 4 2 10.5 10 0.5 3 3
Falco et al. [117] 400 21.0 3.3 7.5 0.0 0.0 2.0 2.3 – – 2.8 0.0 – –
Falguera et al. [118] 660 34 2 5 2 3 9 16 11 1 4 5 4
Garbino et al. [119] 318 12.6 6 4.4 1.6 1.6 7.5 5.3
GarciaVidal et al. [58] 1634 26 7 7 <1 1 1 2 1 1 <1 <1
Ginesu et al. [37] 520 10.8 32.9 0.4 0.9
Gomez et al. [38] 342 12.6 5.6 1.5 0.0 0.3 0.0 3.2 6.1 6.1 0.0 0.0 – –
Gutierrez et al. [120] 493a 16.8 1.8 4.3 0.4 0.2 3.2 2.2 7.7 6.1 0.4 4.1 2.8
Holmberg [121] 147 46.9 9.5 2.7 0.7 2.0 0.0 5.4 – – 1.4 0.0 10.9 10.2
Hone et al. [122] 50 20.0 16.0 4.0 0.0 2.0 2.0 4.0 – – 0.0 0.0 20.0 10.0
Huang et al. [123] 389b 3.1 20.6 0.5 1.5 0.3 6.2 10.8 4.4
Jennings et al. [27] 304 31 11 4 2 3 31 10
Johansson et al. [18] 184 38 5 1 2 4 8 29 8
Johnstone et al. [67] 193 7 1 <1 1 2 3 2 2 0 0 15 4
Leesik et al. [124] 439 10.5 1.1 2.0 5.7 18.0 3.2 3.0 2.5
Levy et al. [125] 116 25.9 11.2 4.3 2.6 0.9 6.9 3.4 – – 0.9 0.0 4.3 –
Logroscino et al. [46] 613 5.9 3.6 2.8 1.1 0.8 3.9 3.3 4.2 – – 3.1 –
Lorente et al. [47] 114 35.1 0.9 1.8 2.6 0.0 2.6 9.6 1.8 – 0.9 – –
Macfarlane et al. [126] 127 75.6 3.1 15.0 2.4 0.0 0.8 2.4 – – 5.5 0.8 8.7 5.5
Marrie et al. [127] 539 2.2–8.1
McNabb et al. [128] 80 50.0 6.3 1.3 3.8 0.0 1.3 0.0 – – 0.0 0.0 6.3 6.3
Menendez et al. [51] 184 23.9 1.6 0.5 0.0 0.0 1.6 14.1 0.5 0.0 1.1 1.6 1.6
Michetti et al. [52] 60 8.3 6.7 11.7 1.7 1.7 3.3 8.3 6.7 1.7 0.0 1.7 1.7
Miyashita et al. [109] 400 26.3 13 1.5 3.3 3.5 4 2 9.3 1.3 0.5 3
Ortqvist et al. [129] 277 46.2 3.6 3.6 0.7 1.1 1.4 9.7 1.1 0.0 1.1 0.0 15.5 2.5
Ostergaard and Andersen 1993 [130] 254 13.8 6.3 3.1 0.4 0.8 2.0 3.9 – – 1.2 0.0 – –
Pareja et al. [131] 165 7.3 1.8 2.4 2.4 0.0 27.3 10.3 – – 1.2 10.9 18.2 13.3
Ruf et al. [132] 442 15.4 2.5 3.8 2.7 0.0 2.5 9.3 – – 3.2 0.0 8.8 4.1
Ruiz et al. [54] 395 16.5 6.3 4.3 1.8 1.0 6.3 3.3 3.8 0.5 2.8 9.9 5.8
Saito et al. [26] 232c 24.6 18.5 3.9 3.4 2.2 1.7 0.4 5.2 8.7 6.5 2.2 0.9 16.4
Schneeberger et al. [133] 159 11.3 10.6 2.5 3.8 3.8 8.2 12 3
Socan et al. [55] 211 5.7 0.9 2.8 0.5 0.0 1.9 5.7 18.0 0.9 0.5 24.2 –
Sohn et al. [134] 126 13.5 0.8 2.4 0.8 12.5 3.1 6.3 7.1 7.1 0
Song et al. [28] 955 12 6 1 2 1 6 3 6 6
Sopena et al. [56] 330 20.3 2.1 13.9 0.6 0.0 0.3 1.5 15.8 0.0 1.2 – –
Steinhoff et al. [57] 237 8.6 5.1 6.3 7.7 6.3
Wattanathum et al. [25] 147 22.4 2.7 5.4 3.4 17.7 0.7 6.8 16.3
White et al. [135] 210 11.4 1.9 1.4 3.8 0.0 1.4 14.3 – – 1.4 2.9 14.8 12.4
Range 3–76 1–21 1–14 0–4 0–4 0–33 0–12 0–18 0–16 0–18 0–6 0–11 1–24 0–13
SP, Streptococcus pneumoniae; HI, Haemophilus inﬂuenzae; LP, Legionella pneumophila; MC, Moraxella catarrhalis; SA, Staphylococcus aureus; GNEB, Gram-negative enteric bacilli; PA,
Pseudomonas aeruginosa; MP, Mycoplasma pneumoniae; CS, Chlamydia species (all); CPne, Chlamydophila pneumoniae; CPsi, Chlamydophila psittaci; CB, Coxiella burnetii.
a26.8% were outpatients.
b36.2% were outpatients.
c16% were outpatients.
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novel swine-origin inﬂuenza A (H1N1) subtype viruses, which
have rarely predominated since the 1957 pandemic, with fea-
tures of the epidemic similar to those of past inﬂuenza pan-
demics. The new inﬂuenza virus was affecting a younger
population, suggesting relative protection for persons who
were exposed to H1N1 strains during childhood before the
1957 pandemic [73]. Severe pneumonias were reported in
conjunction with the novel inﬂuenza A (H1N1) subtype virus.
Pneumonias were due to the virus and to superinfection by
S. pneumoniae or Staphylococcus.
Microorganisms isolated in hospitalized elderly patients
with CAP are shown in (Table 5). There are large variations,
depending on the elderly threshold, where patients live and
comorbidities. However, Gutierez et al. [74] found that age
has a strong inﬂuence on the incidence of CAP caused by
the main microbial pathogens; ageing is associated with a
higher risk of acquiring pneumonia by S. pneumoniae,
inﬂuenza virus and Chlamydia species. Ingarﬁeld et al. [75]
emphasize that enterobacteriacae accounted for more than
25% of isolates in patients older than 65 years.
Table 6 provides microbiological aetiologies of airway
infection in patients with COPD exacerbation, as found in
studies using various methods. Recent studies of the microbi-
ology of acute exacerbations of chronic bronchitis found an
TABLE 4. Aetiology of community-acquired pneumonia in adults admitted to an ICU (%). (Blank boxes indicate organism not
sought)
Reference n SP HI LP SA GNEB MP CS CPsi CB Virus Inﬂuenza
Alkhayer et al. [136] 18 16.7 0 11.1 5.6 0 0 5.6 0 16.7 0
Almirall et al. [137] 58 17.2 1.7 8.6 0 6.9 0 1.7 0 1.75 –
BTS [138] 60 18.3 11.7 11.7 5 3.3 6.7 0 0 0 8.3 5.0
El Solh et al. [36] 57 14 7 9 7 14 2
Gowardman and Trent [39] 32 18.4 9.2 11.6
Hirani and Macfarlane 1997 [41] 57 17.5 0 15.8 12.3 1.8 0 5.3 0 10.5 8.8
Leroy et al. [139] 299 26.8 8.7 0 19.1 15.1 0.7 1.7 0 – –
Moine et al. [140] 132 32.6 10.6 3.0 3.8 10.6 0.8 0.8 1.5 5.35 1.5
Olaechea et al. [53] 262 11.5 3.8 8.0 3.8 3.1 3.1 1.5 0 1.95 –
Ortqvist et al. [141] 53 17.0 1.0 9.0 0 7.0 0 2.0 0 0
Pachon et al. [142] 67 17.9 3.0 10.4 1.5 6.0 0 0 0 0 1.5 1.5
Paganin et al. [143] 112 42.9 0.9 1.8 1.8 26.8
Rello et al. [144] 58 22.4 0 13.8 0 8.6 0 0 0 0 1.75 1.7
Rello et al. [145] 204 20.1 5.3 11.2 2.4 5.8 0.9
Sorensen et al. [146] 36 33.3 8.33 8.3 8.3 2.8 0 0 0 0 13.9 2.8
Torres et al. [147] 92 15.2 0 14.1 1.1 9.8 6.5 0 0 0 – –
Woodhead et al. [148] 50 32 0 30.0 10 0 2 0 0 0 8.0 4.0
Range 12–43 0–12 0–30 0–19 0–27 0–7 0–2 0–6 0–2 0–17 0–9
SP, Streptococcus pneumoniae; HI, Haemophilus inﬂuenzae; LP, Legionella pneumophila; SA, Staphylococcus aureus; GNEB, Gram-negative enteric bacilli; MP, Mycoplasma pneumoniae;
CS, Chlamydia species (all); CPsi, Chlamydophila psittaci; CB, Coxiella burnetii.
TABLE 5. Microorganisms isolated in hospitalized elderly patients with community-acquired pneumonia (CAP) (%). (Blank
boxes indicate organism not sought)
Reference n Patients SP HI LP MC SA GNEB MP CS CB Virus Inﬂuenza Aspiration
El-Solh et al. [36] 57 ‡80 years
Home
14 7 9 4 7 17 2 2 2
El-Solh et al. [36] 47 ‡80 years
Nursing Home
9 2 0 2 29 20 0 0
Fernandez-Sabe´
et al. [149]
305 ‡80 years
Home
23 5 1 3 0.7 0.3 0 8 10
Flamaing 2003 [66] 165 ‡80 years
Home & Nursing Home
3.6 1.2 4.2 0.6 30.9 26.1
Gutierrez et al. [21] 136 ‡75 years
Home
19.1 0.7 1.5 0 0 6.6 2.2 3.7 3.7 2.2
Huang et al. [123] 126 ‡60 years 2.4 14.3 0.8 0.8 2.4 12.7 7.1 6.3
Jokinen et al. [42] 140 ‡60 years Home 48 4 3 3 13 12 0
Riquelme et al. [150] 101 ‡65 years
Home
18.8 3 1 3 8.9 5.9
Saito et al. [26] 114 ‡65 years
Home
28. 20.2 2.6 3.5 3.5 7.9 1.8 9.6 0.9 13.2
Zalacain 2003 [151] 503 ‡65 years
Home & Nursing Home
19.5 5.4 3.8 0.6 1.6 4.4 2.0 2.6 2.2 1.2 0.6
Range 2–48 2–20 0–9 0–4 7–29 3–20 0–7 2–13 0–6 0–31 0–26
SP, Streptococcus pneumoniae; HI, Haemophilus inﬂuenzae; LP, Legionella pneumophila; MC, Moraxella catarrhalis; SA, Staphylococcus aureus; GNEB, Gram-negative enteric bacilli; MP,
Mycoplasma pneumoniae; CS, Chlamydia species (all); CB, Coxiella burnetii.
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inﬂuence of the baseline level of lung function on pathogens
(typical and atypical bacteria and/or virus) found in respira-
tory secretion samples [76–83]. P. aeruginosa should be sus-
pected in patients who have been treated with antibiotics
and in those not vaccinated against inﬂuenza [84]. Both
short-term colonization followed by clearance and long-term
persistence of P. aeruginosa are observed. While serum anti-
body responses do not mediate clearance of P. aeruginosa,
mucoid strains persist in the airways [85].
The microbiological pattern of airway infection may also
differ between pneumonic and non-pneumonic hospitalized
exacerbations of COPD, as shown in a prospective study of
240 patients. Identiﬁcation of a pathogen was more frequent
in pneumonic cases (96% vs. 71%), in which S. pneumoniae
and viruses were more frequent (43% and 78% vs. 18% and
46%, respectively) [86]. Respiratory viruses are more fre-
quently found in induced sputum of hospitalized patients with
COPD exacerbations than in control stable COPD subjects
(47% vs. 10%), the most frequent viruses being rhinovirus,
inﬂuenza, parainfuenza and RSV. However, if exacerbations of
chronic bronchitis and/or COPD may be due to viral and/or
bacterial infection, such infections may occur without exacer-
bation [87]. Finally, bacterial exacerbations of COPD could
be related to the appearance of new strains of S. pneumoniae,
H. inﬂuenzae or M. catarrhalis in the colonized airways [88].
Only a few studies assessed the microbiological pattern of
airway colonization in bronchiectasis, and no study has inves-
tigated the microbiological aetiology of exacerbations. The
main results for steady state bronchiectasis are provided in
Table 7; they highlight the high frequency of Pseudomonas
infection, particularly in the case of impaired lung function.
In a 2-year prospective study of 77 patients with clinically
stable bronchiectasis, multivariate analysis found that early
diagnosis of the disease (before 14 years of age), reduced
FEV1 (<80% predicted) and varicose-cystic bronchiectasis are
risk factors for bronchial colonization with pathogenic bacte-
ria, mainly H. inﬂuenzae and P. aeruginosa (odds ratio: 3.92,
3.91 and 4.80, respectively) [89]. In a study of 100 patients
with steady-state bronchiectasis, the presence of P. aeruginosa
in the sputum was associated with a lower FEV1/FVC ratio
(60% vs. 72% in the absence of a pathogenic microorganism)
and higher volume of daily sputum production (1–6 score: 3
TABLE 6. Aetiology of exacerbations in patients with COPD (%). (Blank boxes indicate organism not sought)
Reference Sample n SP HI MC SA GNEB PA MP CS CPne CPsi CB Virus Inﬂuenza PI RV Adv RSV
Alamoudi [78] Sputum 139 4 12 25 9 12
Beaty et al. [152] Serology 44 4.5
Carilli et al. [153] Serology 46 8.7 8.7 4.3 0 17.4
Eadie et al. [154] Serology 47 4.3 2.1 23.4 0
Eller et al. [76] Sputum 211 9 7.6 4 7.1 18.9 6.6
Erkan et al. [155] Sputum, Serology 75 5 35 6 1 9 17
Fagon et al. [156] PSB 54 8 26 3.5 4.5 6 3.5
Groenewegen and
Wouters 2003 [157]
Sputum 171 14.0 22.2 2.9 2.3 7.6
Gump et al. [158] Serology 116 27.6 42.24 10.3 21.6 6.9 0.8 33.6 12.9 7.8 3.4 4.3
Hutchinson et al. [81] Sputum, Swab,
Serology
148 5 11 2 2 7 6 1 2 1 1 23 2 1 18 1 1
Karnak et al. [159] Serology 38 34.0 34.0
Ko et al. [160] Sputum 418 4.0 23.1 2.0 1.2 5.2 6.3
Ko et al. [83] Sputum, Swab,
Serology
643 4 10 3 0 4 4 0 0 5 1 2
Lamy et al. [161] Serology 49 2.0 28.6 24.5 6.1
Lieberman et al. [162] Serology 62 11.3 11.3
McManus 2008 [79] Sputum 136 37 2 24 7 2
McNamara et al. [163] Serology 42 9.5 0 0 42.8 11.9
Miravitlles et al. [77] Sputum 91 10 22 9 7 15
Mogulkoc et al. [164] Serology
Sputum
49 8.2 8.2 6.1 6.1 22.4 22.4
Monso` et al. [165] PSB 29 10.3 34.5 6.9 6.9
Murphy et al. [166] Sputum 104 10
Papi et al. [167] Sputum 64 12.5 14.1 10.9 6.3 4.7 6.3 48.4 10.9 3 27 6
Roche et al. [80] Sputum 200 8 26 6 6 9
Rohde et al. [168] Sputum
Nasal lavage
85 56 20 7 25 15
Rosell et al. [169] PSB 86 7 30 7 0 16 9
Ross et al. [170] Serology 125 0 0 0 0 10.4 1.6 3.2
Seemungal et al. [171] Serology
Culture
168 0 0.6 0.6 5.4 0.6 23.2
de Serres et al. [172] Sputum, Swab,
Serology
108 4 5 4 10 8 7 1 32 9 6 3 7
Soler et al. [173] PSB 50 8.0 22.0 8.0 8.0 18.0 18.0 14.0 2.0 2.0 12.0 10.0
Range 8–28 0–42 3–11 4–22 5–19 0–18 0–10 0–34 0.34 12–49 0–29 0–25 0–43 0–17
SP, Streptococcus pneumoniae; HI, Haemophilus inﬂuenzae; MC, Moraxella catarrhalis; SA, Staphylococcus aureus; GNEB, Gram-negative enteric bacilli; PA, Pseudomonas aeruginosa;
MP, Mycoplasma pneumoniae; CS, Chlamydia species (all); CPne, Chlamydophila pneumoniae; CPsi, Chlamydophila psittaci; CB, Coxiella burnetii; PI, Para-inﬂuenza; RI, Rhino-virus; RSV,
Respiratory syncytial virus.
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vs. 1) [90]. In that study, FEV1/FVC <60% and high sputum
output were independently associated with an increased risk
of sputum isolation of P. aeruginosa (odds ratio: 3.1 and 4.7,
respectively).
Conclusion
There has been no major change in causative pathogens for
LRTI. More information is available about the frequency of
polymicrobial infections, including viral infections. PVL-pro-
ducing Staphylococcus aureus has emerged as a new cause,
often of severe CAP, but currently remains uncommon.
What information is available about the frequency of
antimicrobial resistance in these settings
Streptococcus pneumoniae. Beta-lactams: The prevalence of
resistance to penicillin and other drugs among pneumococci
has considerably complicated the empirical treatment of
respiratory tract infections. Worryingly, the majority of
resistant isolates are resistant to multiple classes of antimi-
crobials, which has a serious impact on many ﬁrst-line anti-
microbial therapies.
The mechanism of resistance to penicillin and other b-lac-
tams is due to alterations of penicillin-binding proteins (PBP).
PBPs interact with b-lactams enzymatically by forming a
covalent complex via the active-site serine. The loss of afﬁn-
ity for the PBPs affects all b-lactams, although this may vary
substantially depending on the drug. The afﬁnity for a given
b-lactam is different for different PBPs, and conversely, one
PBP has distinct afﬁnities for different b-lactams. Therefore
point mutations reducing the afﬁnity for one b-lactam do not
necessarily affect the afﬁnity for another compound [178].
However, National Committee for Clinical Laboratory Stan-
dards (NCCLS) guidelines state that a pneumococcal isolate
that is susceptible to penicillin can be considered susceptible
to other b-lactams. It is generally accepted that the MICs of
amoxicillin and extended-spectrum cephalosporins are usually
equal to or two to four times lower than the MIC of benzyl-
penicillin. However, pneumococci resistant to amoxicillin and
or extended-spectrum cephalosporins with the MICs of
these agents equal to or 1 dilution higher than the MIC of
penicillin have been identiﬁed [179].
Pneumococci with decreased susceptibility to penicillin
have a much higher rate of resistance to other classes of
antibiotics, as has been mentioned above. Carbapenems,
imipenem, meropenem and ertapenem, are the most active
b-lactams available against PRSP. Among parenteral cephalo-
sporins, those with good activity are cefotaxime, ceftriaxone,
cefepime and cefpirome. It is important to note that other
parenteral third-generation cephalosporins are considerably
less active, for example ceftizoxime and ceftazidime; the
latter has been linked to a poor clinical response [180].
Amoxicillin remains the most active of all oral b-lactams,
and among cephalosporins, cefditoren and cefpodoxime are
most active, then cefuroxime and cefprozil. The use of ce-
furoxime in cases of bacteraemic pneumococcal pneumonia
caused by penicillin non-susceptible strains has been linked
to an increased mortality [181].
The prevalence of penicillin-resistant Streptococcus pneumo-
niae (PRSP) and multidrug-resistant SP varies between regions.
Data on the prevalence of antibiotic resistance among Strepto-
coccus pneumoniae has been regularly produced by the EARSS
project, a European-wide network of national surveillance sys-
tems, providing reference data on antimicrobial resistance for
public health purposes. This network receives funding from
the European Commission (http://www.earss.rivm.nl).
In 2008, 1152 (10%) of the 11 584 invasive S. pneumoniae
isolates reported by 32 countries were non-susceptible to
penicillin (Fig. 1). Penicillin non-susceptible S. pneumoniae
(PNSP) shows a heterogeneous picture in Europe. Most
northern European countries had levels of non-susceptibility
below 5%, but Finland (11%, n = 642) and Ireland (23%,
n = 441) reported relatively high levels. High levels of PNSP,
above 25%, were mainly reported from southern and eastern
Europe, Cyprus (43%, n = 14), France (30%, n = 557),
Hungary (27%, n = 166), Malta (47%, n = 17) and Turkey
(34%, n = 97). The level of penicillin non-susceptibility in Fin-
TABLE 7. Microorganisms isolated in inpatients with non-cystic ﬁbrosis bronchiectasis (%). (Blank boxes indicate organism not
sought)
Reference Sample n SP HI MC SA GNEB PA MP NTM
Angrill et al. [89] PSB 75 8 32 3 18 15 4 –
Chan et al. [174] Sputum 32 – 19 – 53 34 – –
Ho et al. [90] Sputum 100 6 10 5 38 33 2 3
King et al. [175] Sputum 89 7 47 8 4 3 12 2 2
Nicotra et al. [176] Sputum 123 10.6 30.1 2.4 7.3 44 30.9 – 22.8
O’Donnell et al. [177] Sputum 349 – – – – 25 – –
Range 6–11 10–32 3–7 18–53 15–33 2–4 3–23
SP, Streptococcus pneumoniae; HI, Haemophilus inﬂuenzae; MC, Moraxella catarrhalis; SA, Staphylococcus aureus; GNEB, Gram-negative enteric bacilli; PA, Pseudomonas aeruginosa; MP,
Mycoplasma pneumoniae; NTM, non-tuberculous Mycobacteria.
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land and Ireland has risen signiﬁcantly from 2005. The two
countries with the highest levels of PNSP in 2007 (France
and Israel) showed signiﬁcant decreasing rates of PNSP dur-
ing the past years. Lithuania and Norway (the latter only sig-
niﬁcantly for the laboratories reporting consistently in the
last 4 years) also showed decreasing trends for PNSP. In Bel-
gium, the proportions of PNSP as well as PRSP continued to
decrease signiﬁcantly in 2008. In Croatia, Hungary, Ireland
and Turkey a signiﬁcant increase was also observed, but only
for the percentage of fully resistant isolates (see Fig. 1).
The changes in the distribution of serotypes compared with
2007 were small. Serogroups 1 and 19 were still the most
prevalent ones, whereas serogroup 7 and serogroup 3 became
slightly more prevalent, and serogroup 14 became less preva-
lent in the population. The highest resistance proportions
were identiﬁed in serogroups 1, 6, 9, 14, 19F and 33, of which
all but 1 and 33 are included in the seven-conjugate vaccine.
Another recent survey of interest was performed in east-
ern and southern Mediterranean countries. Over a 36-month
period, from 2003 to 2005, the ARMed project collected
1298 susceptibility test results of invasive isolates of S. pneu-
moniae from blood and spinal ﬂuid cultures routinely pro-
cessed within 59 participating laboratories situated in Algeria,
Cyprus, Egypt, Jordan, Lebanon, Malta, Morocco, Tunisia and
Turkey. Overall, 26% (335) of isolates were reported as
non-susceptible to penicillin, with the highest proportions
being reported from Algeria (44%) and Lebanon (40%) [182].
In the US, the incidence of invasive pneumococcal disease
due to penicillin-resistant 19A isolates increased from 6.7%
to 35% between 1998 and 2005 (p <0.0001). Of 151 penicil-
lin-resistant 19A isolates, 111 (73.5%) belonged to the rap-
idly emerging clonal complex 320, which is related to
multidrug-resistant Taiwan (19F)-14 [183]. The importance
of these ﬁndings is the high levels of penicillin resistance
among strains with this serotype (amoxicillin MIC, ‡4 mg/L;
cefotaxime MIC, ‡2 mg/L), and their frequent multiresis-
tance, precluding the use of any oral b-lactam for the treat-
ment of infections caused by these resistant strains.
Of special concern, is the increase in some European
countries of MDR strains of serotype 19A, particularly in
Spain and France [184].
The new susceptibility breakpoints for S. pneumoniae, pub-
lished by the Clinical and Laboratory Standards Institute
(CLSI) in January 2008, were the result of a re-evaluation that
showed clinical response to penicillin was being preserved in
clinical studies of pneumococcal infection, despite reduced
susceptibility response in vitro. Antimicrobial susceptibility
breakpoints are currently established based on (i) the pharma-
cokinetic and pharmacodynamic properties of an antimicrobial
agent and (ii) data correlating individual MIC results with
patient outcomes. Under the former criteria, susceptible,
intermediate and resistant MIC breakpoints for penicillin were
£0.06, 0.12–1 and ‡2 mg/L, respectively, for all pneumococcal
isolates, regardless of clinical syndrome or route of penicillin
administration. Those breakpoints remain unchanged for
patients without meningitis who can be treated with oral peni-
cillin (e.g. for outpatient pneumonia). For patients without
meningitis who are treated with intravenous penicillin, the
new breakpoints are £2, 4 and ‡8 mg/L, respectively.
The changes in penicillin breakpoints for S. pneumoniae
have the potential to allow clinicians to increase use of peni-
cillin to treat penicillin-susceptible non-meningitis pneumo-
coccal infections, instead of using broader-spectrum
antimicrobials. Its use is encouraged to prevent the spread of
antimicrobial-resistant S. pneumoniae and also the spread of
methicillin-resistant Staphylococcus aureus and Clostridium difﬁ-
cile, which can result from use of broader-spectrum antimi-
crobials [185]. In accordance with the penicillin breakpoints,
the doses of suitable b-lactam agents for the treatment of
hospitalized patients with pneumonia when Streptococcus
pneumoniae is suspected are: penicillin G 2 g (3.2 mU) i.v.
Q4 h should be adequate for strains with a penicillin MIC of
£8 mg/L; dose to be adjusted for renal impairment; ceftriax-
one 1 g i.v. or i.m. Q 12 h or cefotaxime 2 g i.v. Q6 h,
should be adequate for strains with a MIC of £8 mg/L [186].
The new formulation of amoxicillin-clavulanic acid (2 g/125
q12 h) available in some European countries, is able to eradi-
cate amoxicillin-resistant strains (MICs, 4–8 mg/L), as shown
in two recent randomized clinical trials (RCTs) [187].
Macrolides: In the EARSS database 10 982 (95%) invasive
S. pneumoniae isolates had susceptibility results for erythro-
mycin in 2008. From the 32 countries reporting data, 1655
FIG. 1. Streptococcus pneumoniae: proportion of invasive isolates
non-susceptible to penicillin (PNSP) in 2008. *These countries did
not report any data or reported <10 isolates.
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(15%) isolates were reported as non-susceptible to erythro-
mycin. Three countries reported erythromycin non-suscepti-
bility below 5% (Czech Republic (n = 243), Estonia (n = 53)
and Bulgaria (n = 24)). On the other hand, ﬁve countries
reported non-susceptibility proportions above 25%, namely
Italy (27%, n = 154), Turkey (29%, n = 97), France (31%,
n = 557), Hungary (32%, n = 158) and Cyprus (29%, n = 14).
A very pronounced increase of erythromycin resistance was
reported from Turkey (10% in 2005 vs.29% in 2008) and
from Ireland, only signiﬁcant for the selected laboratories.
The proportion of isolates non-susceptible to erythromycin
in Belgium, France and the UK continued to decrease, and
now also Germany, the Netherlands and Norway have
reported signiﬁcant decreasing rates with respect to this
(see Fig. 2).
In another survey, during the same time period, the high-
est proportions of pneumococci that were not susceptible
to erythromycin were reported from Malta (46%) and Tuni-
sia (39%) [182].
Macrolide resistance in S. pneumoniae occurs by two main
mechanisms: target-site modiﬁcation or efﬂux of the drug
out of the cell. The most common form of target-site modiﬁ-
cation is a speciﬁc adenine residue on the 23S rRNA
(A2058) that is dimethylated by an rRNA methylase. The
predominant methylase responsible for macrolide resistance
in S. pneumoniae is encoded by erm (B). This methylation is
thought to lead to conformational changes in the ribosome,
resulting in decreased binding of all macrolide, lincosamide
and streptogramin antibacterials (the so-called MLSB pheno-
type). The pneumococci harbouring erm (B) gene exhibits
highs to very high levels of resistance to all macrolides, with
a MIC90 of both clarithromycin and azithromycin of 256 mg/
L or more [188,189].
Macrolide efﬂux is mediated by the product of the mef
(A) gene, which usually causes MICs lower than the erm (B)
isolates (MICs of 1–32 mg/L) and retains susceptibility to
clindamycin (the so-called M-phenotype) [190]. Much more
rarely, mutations at different positions in domains V and II of
23S rRNA and in genes that encode the ribosomal proteins
L4 and L22 have been identiﬁed as a cause of macrolide
resistance [191].
Although it is not surprising that highly resistant strains
(MIC, ‡16 mg/mL) may lead to clinical failure, the relevance
of low-level resistance (MIC, 0.5–8 mg/mL) has been brought
into question. Early this decade, a matched case-control study
of patients with bacteraemic pneumococcal infections showed
that breakthrough bacteraemia with an erythromycin-resis-
tant isolate occurred in 18 (24%) of 76 patients taking a mac-
rolide compared with none of the 136 matched patients with
bacteraemia with an erythromycin-susceptible isolate [192].
These results established that macrolide resistance among
pneumococci, including low level erythromycin-resistant iso-
lates (M phenotype), is a cause of failure of outpatient pneu-
monia therapy. A more recent population-based case-control
study from Toronto has conﬁrmed these results [193].
Macrolide resistance contributes to an increased risk of
macrolide failure, irrespective of the underlying resistance
mechanism or the degree of elevation in erythromycin MIC.
Therefore, it would be wise to avoid empirical macrolide
therapy when a patient is at risk of being infected with a mac-
rolide-resistant pathogen, either as a result of patient-speciﬁc
characteristics or the overall rate of resistance in the commu-
nity. Clinical parameters associated with macrolide resistance
among pneumococci include macrolide exposure within the
previous 3 months, recent use of a penicillin or trimethro-
prim–sulphamethoxazole, extremes of age, HIV infection and
exposure to siblings colonized with resistant isolates [194].
The issue of whether the outcome of bacteraemic pneu-
mococcal pneumonia is improved with the use of combina-
tion antibiotic therapy vs. monotherapy is still not resolved.
The mechanism for the potential beneﬁt of combining a mac-
rolide with a b-lactam is uncertain, and may be multifactorial,
such as providing cover for atypical pathogens, unrecognized
polymicrobial infection, and/or additional cover for drug-
resistant infections, synergy between these two classes of
agents, and immunomodulatory properties of the macrolides.
Macrolides, at sub-MICs, but not other classes of antibiotic,
subvert the production of pneumolysin, even in the presence
of (and irrespective of the mechanism of) macrolide resis-
tance in S. pneumoniae [195].
Fluoroquinolones: Resistance to quinolones occurs in a
stepwise fashion, with mutations being observed ﬁrst in
FIG. 2. Streptococcus pneumoniae: proportion of invasive isolates
non-susceptible to erythromycin in 2008. From EARSS. *These coun-
tries did not report any data or reported <10 isolates.
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either parC or gyrA leading to decreased ﬂuoroquinolone
susceptibility. Strains usually become fully resistant with the
addition of a mutation in the other target gene (either gyrA
or parC) [196]. Mutations in parE and gyrB and efﬂux pump
are less important mechanisms of resistance.
Emergence of resistance during the course of antimicrobial
therapy is most likely to develop from strains that already
carry one quinolone resistance determining region (QRDR)
as they require only one additional mutation in one of the
other target genes to become resistant. The concept of
mutant prevention concentration reﬂects the concentration
that prevents the growth of ﬁrst-step mutants. Based on
their potential for restricting the selection of resistant
mutants, not all ﬂuoroquinolones are equal and can be classi-
ﬁed accordingly; their ability to prevent the selection of
mutants is in descending order: moxiﬂoxacin, trovaﬂoxacin,
gatiﬂoxacin, grepaﬂoxacin and levoﬂoxacin [197].
Fluoroquinolone resistance among S. pneumoniae remains
rare in Europe. The use of older agents and incorrect dosing
are the main drivers of resistance. The Alexander Project
reported ﬂuoroquinolone resistance among pneumococci of
<1% in 2001 in northern and southern Europe (http://
www.alexandernetwork.com). The PROTEKT study identi-
ﬁed no quinolone-resistant isolates in northern Europe and
only 1.3% of S. pneumoniae from southern Europe were
resistant to levoﬂoxacin (http://www.protekt.org.). However,
the prevalence of ﬁrst-step mutants is largely unknown.
More recent surveys suggest that the prevalence of resis-
tance to levoﬂoxacin and 8-methoxi ﬂuoroquinolones (moxi-
ﬂoxacin, gatiﬂoxacin) in southern Europe, speciﬁcally in Italy
and Spain, appears to be around 2–3% [198].
Tetracyclines and other agents: In many countries of the
world chloramphenicol, co-trimoxazole and tetracyclines
have reached such a level and prevalence of resistance that
they are no longer a good option for empirical therapy in
RTI of pneumococcal aetiology. Thus, resistance to trimetho-
prim-sulphamethoxazole is reported in approximately 35% of
isolates. Tetracycline resistance in pneumococi remains rela-
tively high in some European countries. However, no recent
comprehensive surveillance data on tetracycline resistance
are available. Early this decade, among invasive isolates, up to
11.5% were reported to be resistant to tetracycline, and
among non-invasive isolates, the prevalence of tetracycline
resistance can be as high as 42% in southern Europe. In
other European countries, recent studies have shown low
resistant rates of tetracycline resistance. Thus, in the UK and
Ireland, out of 1388 invasive isolates, only 4% were resistant,
and among 5810 respiratory isolates, 7.6% were resistant
[199].
Haemophilus inﬂuenzae. Beta-lactams: b-Lactamase produc-
tion is the primary mechanism of resistance among H. inﬂuen-
zae and is a well-known predictor of treatment failure in
community-acquired respiratory tract infections. This can be
overcome with the use of b-lactamase-stable cephalosporins
or b-lactam plus b-lactamase-inhibitor combinations. In addi-
tion, H. inﬂuenzae isolates carrying amino acid substitutions
in the ftsI gene (encoding PBP 3) are phenotypically recog-
nized as b-lactamase negative ampicillin resistant (BLNAR),
which leads to the loss of susceptibility to aminopenicillin
and some cephalosporins.
In Europe, resistance rates of Haemophilus inﬂuenzae
against b-lactams, in spite of large inter-regional differences,
seem to decline due to a decreasing number of BL-producing
strains. In a recent surveillance study of antibiotic resistance
in H. inﬂuenzae, the mean prevalence of b-lactam producers
was 7.6%, with a range of 0.7–17.6% [200]. Although rare, b-
lactamase-negative ampicillin-resistant (BLNAR) and b-lac-
tamase-positive amoxicillin/clavulanate-resistant (BLPACR)
H. inﬂuenzae are of concern where they exist.
Macrolides: Azithromycin is the most active of these
agents against H. inﬂuenzae, with a MIC four- to eightfold
lower than erythromycin (azithromycin MICs, <0.25–4 mg/L).
On the other hand, the existence of efﬂux pumps leads to
loss of susceptibility to macrolides in more than 98% of H. in-
ﬂuenzae strains [201]. It appears that the vast majority
(>98%) of H. inﬂuenzae strains have a macrolide efﬂux mech-
anism, with a few of these being hyper-resistant (1.3%; azi-
thromycin MICs >4 mg/L) due to one or several ribosomal
mutations. Occasional hypersusceptible strains (1.8%; azithro-
mycin MICs <0.25 mg/L) are found without any underlying
mechanism of resistance and appear to be the only truly
macrolide-susceptible variants of H. inﬂuenzae.
The prevalence of resistance is based on the use of
pharmacokinetic/pharmacodynamic breakpoints; large dis-
crepancies are observed in terms of susceptibility, by use of
CLSI breakpoints. So, for instance, the rate of susceptibility
to clarithromycin can shift from >99% to 5% (by use of the
PK/PD breakpoints).
Fluoroquinolones and other agents: Fluoroquinolone resis-
tance remains rare with H. Inﬂuenzae.
Prevalence of tetracycline resistance: few recent data are
available. A survey in the UK and Ireland showed a signiﬁcant
though slow downward trend (p <0.00008) in tetracycline
non-susceptibility, which reduced from 3.5% in 1999/2000 to
1.2% in 2006/2007 and dipped as low as 0.9% in 2004/2005
[202].
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In Greece, resistance to tetracycline increased from 1.6%
in 1996 to 38% in 2005 [203].
Resistance to other orally administered agents, such as tri-
methoprim-sulphamethoxazole (TMP-SMX) and chloramphe-
nicol, is well known. The overall frequencies of resistance to
TMP-SMX remain around 18% in a recent survey in the US
[204].
Moraxella catarrhalis. The susceptibility of M. catarrhalis has
changed little since 1999. It is interesting to note that,
despite almost universal b-lactamase prevalence, resistance
to other antibacterial agents has not developed in M. catarrh-
alis. Clinicians should assume that all isolates of M. catarrhalis
are resistant to amoxicillin, ampicillin, piperacillin and penicil-
lin. Two types of b-lactamases can be found that are pheno-
typically identical: the BRO-1 and BRO-2 types. Both
enzymes are readily inactivated by b-lactamase inhibitors,
and all isolates are still susceptible to amoxicillin in combina-
tion with clavulanic acid. Other enzyme-stable b-lactams,
macrolides and tetracyclines are still very active against M. ca-
tarrhalis, but rates of TMP-SMX resistance as high as 50%
have been occasionally reported.
Mycoplasma pneumoniae. M. pneumoniae is inhibited by tetra-
cyclines, macrolides, ketolides and ﬂuoroquinolones, with little
variation in MICs among clinical isolates [205,206]. Other
agents that are active at the bacterial ribosome, such as strep-
togramins, chloramphenicol and aminoglycosides, may also
show in vitro inhibitory activity against M. pneumoniae but are
not normally used for therapeutic purposes against this organ-
ism. Clindamycin is active in vitro but its in vivo activity has
never been demonstrated. Due to the lack of a cell wall, myco-
plasmas are resistant to all b-lactams and glycopeptides. Sulph-
onamides, trimethoprim, polymixins, nalidixic acid and
rifampin are also inactive [207]. As tetracyclines and ﬂuoroqui-
nolones are not approved for use in children, macrolides are
generally considered the treatment of choice for M. pneumo-
niae infections in both adults and children.
Since 2000, the emergence of macrolide resistance has
been reported mainly in Asia. In Japan, several recent studies
reported that macrolide-resistant M. pneumoniae isolates
have been spreading since 2000, with prevalence increasing
up to 30.6% according to these studies [208–210]. The
A2058G mutation in domain V of 23S rRNA is the most fre-
quent substitution associated with macrolide resistance in
clinical isolates.
Data regarding current resistance patterns for M. pneumo-
niae in European adult and adolescent patients with CAP are
limited. Macrolide resistance rates of 3.0% in Germany have
been recently reported [211]. In France, among M. pneumo-
niae-positive specimens collected before 2005, no macrolide-
resistant M. pneumoniae isolate was detected. In contrast,
among 51 samples collected between 2005 and 2007, ﬁve
(9.8%) yielded a resistant genotype, suggesting a recent
increase in macrolide-resistant M. pneumoniae isolates in
France [212]. These emerging data suggest that the epidemi-
ological monitoring of macrolide resistance in this species
has become necessary in Europe.
Staphylococcus aureus. In the European setting, S. aureus
remains an unusual primary cause of CAP [213], although it
is an important cause of pneumonia and death following
inﬂuenza [214]. The role of CA-MRSA is even more poorly
deﬁned, although emergent in Europe [215]. Infections due
to CA-MRSA have symptom onset before or within 48 h of
admission to hospital and patients have no signiﬁcant previ-
ous healthcare contact. CAP, which is due to CA-MRSA,
classically presents in a young, previously healthy, individual
with rapidly progressive, severe respiratory disease. The
aggressive nature of CA-MRSA, due to toxin production,
causes massive destruction in previously normal lungs.
CA-MRSA is usually only resistant to the b-lactams and
susceptible to most other antibiotic classes. This difference
in the laboratory ﬁndings may indicate that the patient has a
CA-MRSA isolate as opposed to an HA-MRSA isolate. How-
ever, with time, CA-MRSA is likely to acquire the resistance
genes that will make it more difﬁcult to differentiate from
HA-MRSA by routine antimicrobial susceptibility testing.
Because S. aureus is an uncommon cause of CAP, it does
not need to be covered routinely by the empirical CAP
treatment. However, the severity associated with S. aureus
pneumonia reinforces the importance of performing routine
blood and respiratory cultures in pneumonia patients.
Clindamycin and linezolid markedly suppress the forma-
tion of PVL, a-haemolysin and toxic shock syndrome toxin 1
by suppressing translation but not transcription. Nafcillin, on
the other hand, stimulates toxin production, whereas toxin
levels with use of vancomycin are comparable to those in
control samples not exposed to antibiotics.
As suppression of toxin production may correlate with
improved outcome, vancomycin alone may not be the opti-
mal treatment for pneumonia caused by toxin-producing
CA-MRSA. Although it has not been established that the
combination of a bactericidal agent with a toxin-suppressing
agent, such as clindamycin or linezolid, is associated with
improved outcome, it is the general feeling that vancomycin
should not be used as a single agent in the treatment of
CA-MRSA CAP.
In severe infections there are limited trial data to support
the use of one regimen over another and recommendations
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are largely based on expert advice. Adjunctive therapy, such
as intravenous immunoglobulin, has been successful in some
case reports, but its real contribution is unknown.
What new information is available about the clinical
relevance of antimicrobial resistance in this setting?
The pattern of antimicrobial resistance varies between Euro-
pean countries. Changes in the prevalence of antibiotic resis-
tance among the main respiratory pathogens in Europe have
been reported; continued surveillance of antimicrobial resis-
tance in all common pathogens is essential.
1 In pneumococci, erythromycin MICs >0.5 mg/L predict
clinical failure. The prevalence of resistance in many
countries compromises the efﬁcacy of macrolides in the
treatment of pneumococcal infection. The prevalence of
resistance will dictate the need to reassess current rec-
ommendations for the treatment of CAP.
2 Adequate choice and dosing of selected b-lactams is still
useful in the treatment of extrameningeal pneumococcal
infections. There are no documented failures in patients
with extrameningeal infections due to penicillin-resistant
strains treated with adequate doses of penicillins and
third-generation cephalosporins. Penicillin, 2 g (3.2 mU)
i.v. Q 4 h, should be adequate for strains with a penicillin
MIC of £8 mg/L; adjust dose for renal impairment; ceftri-
axone 1 g i.v. or i.m. Q 12 h or cefotaxime 2 g i.v. Q
6 h, should be adequate for strains with a MIC of £8 mg/
L. A new formulation of Amox/Clav (2 g/125 Q 12 h)
eradicated amoxicillin-resistant strains (MICs, 4–8 mg/L)
in two RCTs. Oral cephalosporins are not adequate for
the treatment of infection caused by strains with penicil-
lin MICs >2 mg/L.
3 Fluoroquinolones are highly active and efﬁcacious against
respiratory pathogens; they should be used in well-
deﬁned circumstances. If the prevalence of ﬁrst-step
mutants is low, the use of the most potent FQ is a logi-
cal choice if resistance has to be avoided/delayed. Previ-
ous exposure to an FQ in the recent past precludes the
use of a member of this class for the empirical treatment
of CAP.
4 Macrolides show, at best, only modest activity against
H. inﬂuenzae. The existence of efﬂux pumps leads to loss
of susceptibility to this class in more than 98% of H. inﬂu-
enzae strains.
5 Among ‘atypicals’, antibiotic resistance is rare and very
seldom responsible for clinical failures.
6 Macrolide resistance in Mycoplasma pneumoniae is rising
in Japan; there is a need for European local surveillance
studies.
7 The role of CA-MRSA in CAP is poorly deﬁned, although
emergent in Europe. CA-MRSA is usually only resistant
to the b-lactams and susceptible to most other antibiotic
classes. The antibiotic treatment of CA-MRSA pneumonia
is not known. As suppression of toxin production may
correlate with improved outcome, vancomycin alone may
not be the optimal treatment for pneumonia. Thus, the
combination of a bactericidal agent with a toxin-sup-
pressing agent, such a clindamycin or linezolid, has been
suggested as the optimal choice.
8 In vivo selection of resistance means that proper use of
antimicrobials is essential.
What new information is available about antimicrobial
pharmacokinetics and pharmacodynamics
The only new information is about the need for high levo-
ﬂoxacin doses (750 mg OD) in the treatment of Pseudomonas
and Klebsiella [216,217]. Two other new studies do now alter
the current guideline recommendations [218,219].
Management Outside Hospital
Introduction
Lower respiratory tract infection is a broad description of a
group of disease entities, encompassing acute bronchitis,
pneumonia and exacerbations of chronic lung disease. In pri-
mary care it is very difﬁcult to differentiate between those
different diseases without doing extensive additional diagnos-
tic tests. Patients can present with cough, dyspnoea, tachyp-
noea, fever, pain in the chest, wheezing and auscultatory
abnormalities. There is huge overlap in presentation between
the different lower respiratory diseases mentioned above and
it is neither feasible nor cost-efﬁcient to do a full diagnostic
work-up in all patients. Therefore an empirical and pragmatic
approach is warranted. The statements and recommendations
below are based on primary care studies, expert opinion and
consensus among members of the working group.
Diagnosis
When should aspiration pneumonia be considered?
Recommendation: Aspiration pneumonia should be con-
sidered in patients with difﬁculties with swallowing who
show signs of an acute LRTI. In these patients a chest X-ray
should be performed [C3].
No new information. Recommendation not changed.
When should left ventricular failure be considered?
Recommendation: Left ventricular failure should be
considered in patients above 65, with either orthopnoea,
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displaced apex beat and/or a history of myocardial infarction,
hypertension or atrial ﬁbrillation.
Low serum levels of atrial natriuretic peptide (Brain
Natriucetic Peptide <40 pg/mL) or N-terminal pro-BNP
<150 pg/mg) make the presence of left ventricular failure
unlikely [C3].
New information. Recommendation not changed.
A number of new studies on the diagnosis of cardiac fail-
ure in primary care were found, but none involving patients
with a cough. The presence of hypertension and atrial ﬁbril-
lation is associated with cardiac failure, and levels of BNP
and NT-proBNP were found to have diagnostic value for
detecting cardiac failure [220–222].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Aspromonte
et al. [220]
To evaluate whether BNP measurement
associated with echocardiography could
effectively stratify patients with new
symptoms
CSS 4A+
Mikkelsen
et al. [221]
To assess diagnostic accuracy of cardiac
peptides in detecting any left ventricular
dysfunction (LVD) in patients referred
from primary care with suspected
HF before institution of medical therapy
CSS 4A+
Fuat
et al. [222]
To test and compare the diagnostic
accuracy and utility of B-type natriuretic
peptide (BNP) and N-terminal B-type
natriuretic peptide (NT proBNP) in
diagnosing heart failure due to left
ventricular systolic dysfunction in patients
with suspected heart failure referred
by GPs to one-stop diagnostic clinics
CSS 4A+
When should pulmonary embolism be considered?
Recommendation: Pulmonary embolism should be consid-
ered in patients with one of the following characteristics: a
history of DVT or pulmonary embolism, immobilization in
the past 4 weeks, or malignant disease [C3].
No new information. Recommendation not changed.
When should chronic airway disease be considered?
Recommendation: In patients with a persistent cough and
at least two of the following, wheezing (either as sign or as
symptom), previous consultations for wheezing or cough,
dyspnoea, prolonged expiration, a smoking history and symp-
toms of allergy, lung-function tests should be considered to
assess the presence of chronic airway disease. In elderly
patients who smoke and present with a cough, COPD
should be considered [B1].
One relevant study indicated that smoking and age
>60 years in combination with a cough is clearly related to
the presence of COPD [223]. One literature review was
recently published that gave a critical report on six studies
on the detection of COPD. The following signs and symp-
toms were mentioned at least three times in those studies:
dyspnoea, wheezing (complaint), previous consultation for
wheezing or cough, self-reported COPD, age, smoking,
wheezing (sign), prolonged expirium and forced expiration
time. The review concluded that variation and weaknesses in
study designs warranted further studies [224].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Van Schayck
et al. [223]
To investigate the effectiveness of case
ﬁnding of patients at risk of developing
chronic obstructive pulmonary disease
CSS 4A+
Broekhuizen
et al. [224]
To review the literature on detection of
COPD in patients with cough in primary
care
MA 1C?
How to differentiate between pneumonia and other respiratory
tract infections
Recommendation: A patient should be suspected of hav-
ing pneumonia when one of the following signs and symp-
toms are present: new focal chest signs, dyspnoea,
tachypnoea, pulse rate >100, fever >4 days. In patients with
a suspected pneumonia a test for serum-level of C-reactive
protein (CRP) can be done. A CRP level of <20 mg/L at pre-
sentation, with symptoms for >24 h, makes the presence of
pneumonia highly unlikely, a level of >100 mg/L makes pneu-
monia likely.
In the case of persisting doubt after CRP testing, a chest
X-ray should be considered to conﬁrm or reject the diagno-
sis [B1].
Two new studies on the diagnostic value of signs, symp-
toms and CRP [225,226] both showed that a combination of
signs, symptoms and CRP does have diagnostic value in
detecting and mainly ruling out pneumonia. Two new studies
on the isolated diagnostic value of CRP conﬁrmed the diag-
nostic value of CRP [227,228].
On the other hand, two reviews on the value of CRP in
this ﬁeld conclude that CRP has no clear diagnostic value in
primary care. The review by van der Meer et al., however,
found excellent positive and negative predictive values, with
a ROC curve with area under the curve of 0.80. Falk et al.
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concluded in their review that the isolated use of CRP will
not be very useful in primary care but state nevertheless in
their discussion that when a physician is in doubt about the
presence of pneumonia, CRP could be helpful to rule out
the disease [229,230].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Flanders
et al. [227]
To evaluate the performance of a rapid,
bedside whole blood C-reactive protein
test as a diagnostic test for pneumonia in
adults
PCS 4A+
Hopstaken
et al. [225]
To assess the diagnostic value of symptoms,
signs, erythrocyte sedimentation rate
(ESR), and C-reactive protein (CRP) for
pneumonia
PCS 4A+
Van de Meer
et al. [229]
To evaluate the diagnostic accuracy of
C-reactive protein in detecting
radiologically proved pneumonia and to
evaluate how well it can discriminate
between bacterial and viral infections of
the lower respiratory tract.
MA 1A?
Graffelman
et al. [226]
To assess the diagnostic value of signs,
symptoms and CRP in detecting pneumonia
PCS 3B+
Holm
et al. [228]
To evaluate the diagnostic value of CRP and
procalcitonine in detecting pneumonia
PCS 3A+
Falk and
Fahey [230]
To assess the diagnostic value of CRP in
detecting pneumonia
MA 1A?
Should the primary care physician test for a possible
microbiological aetiology of LRTI?
Recommendation: Microbiological tests such as cultures
and Gram stains are not recommended [B1].
‘Biomarkers to assess the presence of a bacterial pathogen
are not recommended in primary care’ [A1].
A new systematic review and two observational studies
underlined these recommendations [94,228,229]. New infor-
mation. Recommendation not changed.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Van de Meer
et al. [229]
To evaluate the diagnostic accuracy of
C-reactive protein in detecting
radiologically proved pneumonia and
to evaluate how well it can discriminate
between bacterial and viral infections of
the lower respiratory tract
MA 1A+
Graffelman
et al. [94]
To evaluate the diagnostic value of medical
history, physical examinations and
additional tests in discriminating between
viral and bacterial infections in patients
with acute cough
PCS 3B+
Holm
et al. [228]
To evaluate the diagnostic value of CRP and
PCT in discriminating between bacterial
and viral lower respiratory tract infections
PCS 3A+
Prognosis
How should the risk of complications be assessed in a primary
care patient with LRTI?
Recommendation: Patients with an elevated risk of com-
plications should be monitored carefully and referral should
be considered. In patients over 65 years of age the following
characteristics are associated with a complicated course:
presence of COPD, diabetes or heart failure, previous hospi-
talization in the past year, taking oral glucosteroids, antibiotic
use in the previous month, general malaise, absence of upper
respiratory symptoms, confusion/diminished consciousness,
pulse >100, temperature >38, respiratory rate >30, blood
pressure <90/60 and when the primary care physician diag-
noses pneumonia [A3]. In patients under 65 the working
group thinks that diabetes, a diagnosis of pneumonia and
possibly also asthma are risk factors for complications. For
all age groups, serious conditions such as active malignant
disease, liver and renal disease and other disorders that are
relatively rare in primary care but affect immunocompetence
do also increase the risk of complications [C3].
Several studies have been published, mainly on prognosis
in the elderly. Some of the ﬁndings mentioned above are not
yet validated externally.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Hak et al. [231] To determine prognostic factors for
complications of LRTI among elderly
patients in primary care
RCS 4A+
Seppa et al. [232] To determine which information can be
used to assess the severity of LRTI in
primary care
PCS 3A+
Bauer et al. [233] To validate the CURB, CRB and CRB-65
scores for the prediction of death from
community-acquired pneumonia (CAP)
PCS 3A+
Bont et al. [234] To study predictors of complications of
lower respiratory tract infections in
elderly patients
PCS 3A+
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Bont et al. [235] To validate the CRB-65 rule for elderly
patients in primary care
PCS 3A+
Bont [236] To develop a prediction model for lower
respiratory tract infections in elderly
patients in primary care
PCS 3A+
Treatment
Should symptomatic acute cough be treated?
Recommendation: Cough suppressants, expectorants,
mucolytics, antihistamines, inhaled corticosteroids and bron-
chodilators should not be prescribed in acute LRTI in pri-
mary care [A1].
One new updated Cochrane review on cough medication
concluded that there is no clear beneﬁt from interventions
[237] Some of the studies in this review did report some
beneﬁcial effects from expectorants and antitusive agents,
but these studies were small and suffered from methodologi-
cal ﬂaws. The Cochrane review on the use of bronchodila-
tors in acute cough showed no beneﬁcial effects [238]. One
new RCT on the effects of inhaled ﬂuticasone in patients
with acute cough showed a small effect on symptom severity
in the second week of disease. The clinical relevance of this
small effect is, however, doubtful [239].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Smith
et al. [237]
To assess the effects of oral
over-the-counter cough preparations
for acute cough.
MA 1A)
Smucny
et al. [238]
To determine whether beta2-agonists
improve the symptoms of acute bronchitis
in patients who do not have underlying
pulmonary disease.
MA 1A+
Ponsioen
et al. [239]
To investigate the short-term effects of an
inhaled steroid (ﬂuticasone propionate
(FP)) on cough
RCT 2A+
When should antibiotic treatment be considered in patients with
LRTI?
Recommendation: Antibiotic treatment should be pre-
scribed in patients with suspected or deﬁnite pneumonia
(see How to differentiate between pneumonia and other
respiratory tract infections?) [C1].
Antibiotic treatment should be considered for patients
with LRTI and serious co-morbidity such as:
1 selected exacerbations of COPD (see section ‘Exacerba-
tions of chronic obstructive pulmonary disease’);
2 cardiac failure;
3 insulin-dependent diabetes mellitus; or
4 a serious neurological disorder (stroke, etc.) [C3].
There is one new update of a Cochrane review on the
effects of antibiotics in acute bronchitis, including one large
new trial on the effects of antimicrobial therapy: no new
conclusions on the overall effects on the average adult
patient with acute bronchitis [240,241]. Recommendations
for subgroups are based on consensus.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Little
et al. [241]
To estimate the effectiveness of three
prescribing strategies and an information
leaﬂet for acute lower respiratory tract
infection
RCT 2A+
Smith [240] To assess the effects of antibiotic treatment
for patients with a clinical diagnosis of
acute bronchitis
MA 1A+
What are the indications for antibiotic treatment of acute exacer-
bations of chronic obstructive lung disease (COPD)?
Recommendation: An antibiotic should be given in exac-
erbations of COPD in patients with all three of the
following symptoms: increased dyspnoea, sputum volume
and sputum purulence. In addition, antibiotics should be
considered for exacerbations in patients with severe
COPD [C1].
New information. Recommendation not changed.
A new Cochrane review concluded that antibiotic treat-
ment has beneﬁcial effects in moderately and severely ill
patients with increased cough and purulence of sputum.
However, the authors state that their conclusions are some-
what weakened by the considerable differences in methodol-
ogy and settings between studies. The three studies in
outpatients indicate that there is only a potentially beneﬁcial
effect in patients with three Anthonisen criteria [242].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
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Reference Objective Design Evidence
Ram et al. [242] To conduct a systematic review of the liter-
ature estimating the value of antibiotics in
the management of acute COPD exacerba-
tions
MA 1A+
Which antibiotics should be used in patients with LRTI?
Recommendation: Amoxicillin or tetracycline should be
used as antibiotic of ﬁrst choice based on least chance of
harm and wide experience in clinical practice. In case of
hypersensitivity a tetracycline or macrolide such as azithro-
mycin, clarithromycin, erythromycin or roxithromycin is a
good alternative in countries with low pneumococcal macro-
lide resistance. National/local resistance rates should be con-
sidered when choosing a particular antibiotic. When there
are clinically relevant bacterial resistance rates against all
ﬁrst-choice agents, treatment with levoﬂoxacin or moxiﬂoxa-
cin may be considered [C1].
No clear preferences between available antibiotics can be
given based on short-term beneﬁts or frequency of side-
effects. Clinical trials assessing the effects of antibiotics in pri-
mary care do vary considerably both in quality and methods
regarding their reports on side-effects and adverse events in
subjects. Equally, it is not really possible to compare tenden-
cies to evoke bacterial resistance or rare, but important,
side-effects. All available antibiotic agents that are active
against respiratory pathogens do cause bacterial resistance.
In the following recommendations the newer broad-spectrum
antibiotics are reserved for second-choice escape medication
when the traditional well-known agents cannot be used. Two
new reviews support these recommendations [243,244].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Bjerre
et al. [243]
To summarize the evidence currently
available from randomized controlled trials
(RCTs) concerning the efﬁcacy of
alternative antibiotic treatments for CAP in
ambulatory patients above 12 years of age
MA 1A+
Mills
et al. [244]
To systematically compare beta lactam
antibiotics with antibiotics active against
atypical pathogens in the management of
community-acquired pneumonia
MA 1A+
Is antiviral treatment useful in patients with LRTI?
Recommendation: The empirical use of antiviral treatment
in patients suspected of having inﬂuenza is usually not recom-
mended [B1]. Only in high-risk patients who have typical inﬂu-
enza symptoms (fever, muscle ache, general malaise and
respiratory tract infection), for <2 days and during a known
inﬂuenza epidemic, can antiviral treatment can be considered
[A1].
New information. Recommendation not changed
[245,246].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Cooper
et al. [245]
To review the clinical effectiveness of
oseltamivir and zanamivir for the treatment
and prevention of inﬂuenza A and B
MA 1A+
Jefferson
et al. [246]
To review the evidence of efﬁcacy,
effectiveness and safety of registered
antivirals against naturally occurring
inﬂuenza in healthy adults
MA 1A+
How should patients with LRTI be monitored?
Recommendation: A patient should be advised to return
if the symptoms take longer than 3 weeks to disappear.
A clinical effect of antibiotic treatment should be expected
within 3 days and patients should be instructed to contact
their doctor if this effect is not noticeable. Seriously ill
patients, meaning those with suspected pneumonia and
elderly patients with relevant co-morbidity, should be
followed-up 2 days after the ﬁrst visit.
‘All patients or persons in their environment should be
advised to contact their doctor again if fever exceeds 4 days,
dyspnoea gets worse, patients stop drinking or consciousness
is decreasing’ [C3].
No new information. Recommendation rephrased.
When should patients with LRTI be referred to hospital?
Recommendation: In the following categories of patients,
referral to hospital should be considered:
1 Severely ill patients with suspected pneumonia (the fol-
lowing signs and symptoms are especially relevant here:
tachypnoea, tachycardia, hypotension and confusion).
2 Patients with pneumonia who fail to respond to antibiotic
treatment.
3 Elderly patients with pneumonia and elevated risk of
complications, notably those with relevant co-morbidity
(diabetes, heart failure, moderate and severe COPD,
liver disease, renal disease or malignant disease).
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4 Patients suspected of pulmonary embolism.
5 Patients suspected of malignant disease of the lung [C3].
These recommendations are based on consensus in the
working group. There are no studies comparing different
referral strategies.
Management Inside Hospital
Community-acquired pneumonia
Who should be admitted to hospital?
Recommendation: The decision to hospitalize remains a
clinical decision. However, this decision should be validated
against an objective tool of risk assessment. The CRB-65 is
most practical in its simplicity. In patients meeting a CRB-65
of one or more (except age ‡65 as the only criterion met),
hospitalization should be seriously considered [A3]. Biomar-
kers (e.g. CRP or PCT) have a signiﬁcant potential to
improve severity assessment but have not been sufﬁciently
evaluated for the decision to hospitalize [A3].
Most recent publications have shown that the CURB-score
and its modiﬁcations (particularly CRB-65 score) are compa-
rable to the Pneumonia Severity Index index in terms of pre-
diction of death from pneumonia in both outpatients and
inpatients [233,247–254]. Moreover, the CURB-65 has been
shown to outperform generic sepsis and early warning scores
[255]. In view of its simplicity and the absence of any labora-
tory and radiographic criterion, which may not be easily avail-
able in general practice, the CRB-65 score is recommended
as tool of choice in the assessment of pneumonia severity.
Systolic blood pressure is the best haemodynamic predictor;
diastolic pressure may be neglected [256]. The priority of
clinical judgement and the need to consider non-clinical fac-
tors for decision making about treatment settings is rein-
forced [257–259]. In patients residing in nursing homes, a
predeﬁned clinical pathway can help to reduce hospitalization
by about 50%, with comparable clinical outcomes [260].
Biomarkers (C-reactive protein (CRP)) [228,261–264],
procalcitonin (PCT) [228,263,265,266], D-dimer [267], car-
boxy-terminal provasopressin (CT-proAVO, copeptin) [268],
midregional proatrial natriuretic peptide (MR-pro-ANP)
[266,269,270], midregional proadrenomedullin (MR-ADM)
[271,272], and triggering receptor expressed on myeloid cells
(TREM-1) [273], as well as the adrenal response [274,275],
as an alternative or additional tool for the assessment of
pneumonia severity, have recently gained much attention. It
appears that all of them seem to have a signiﬁcant potential
to predict mortality. Some data suggest that predictive tools
and biomarkers do not reﬂect identical processes and that
biomarkers may improve predictions based on clinical param-
eters [276,277]. However, the optimal use of clinical assess-
ment, including severity scores and biomarkers, remains to
be established. Currently, CRP and PCT are best available
and may be implemented as an additional severity tool; how-
ever, the evidence is still limited. Among all biomarkers
investigated, pro-ADM seems most promising [271,272].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
References Objective Design Evidence
Predictive tools
Aujesky et al. [250] Reasons why emergency
department providers do not rely
on the pneumonia severity index
to determine the initial site of
treatment for patients with
pneumonia
PCS 3A+
Barlow et al.[255] The CURB65 pneumonia severity
score outperforms generic sepsis
and early warning scores in
predicting mortality in
community-acquired pneumonia
RCS 4B+
Bauer et al. [233] CRB-65 predicts death from CAP PCS 3A+
Busing et al. [252] A prospective comparison of
severity scores for identifying
patients with severe
community-acquired pneumonia:
reconsidering what is meant by
severe pneumonia
PCS 3A+
Capelastegui
et al. [251]
Validation of a predictive
rule for the management of
community-acquired pneumonia
PCS 3A+
Chalmers
et al. [267]
Systolic blood pressure is superior
to other haemodynamic
predictors of outcome in
community-acquired pneumonia
PCS 3A+
Ewig et al. [248] Validation of predictive rules and
indices of severity for
community-acquired pneumonia
PCS 3A+
Ewig et al. [249] New perspectives on
community-acquired pneumonia in
388 406 patients. Results from
a nationwide mandatory
performance measurement
programme in healthcare quality
PCS 3A+
Labarere
et al. [257]
Factors associated with the
hospitalization of low-risk patients
with community-acquired
pneumonia in a
cluster-randomized trial
PCS 3A+
Lim et al. [247] Deﬁning community-acquired
pneumonia severity on
presentation to hospital: an
international derivation and
validation study
PCS 3A+
Loeb et al. [260] Effect of a clinical pathway to
reduce hospitalizations in nursing
home residents with pneumonia:
a randomized controlled trial
RCT 2A+
Man et al. [253] Prospective comparison of three
predictive rules for assessing
severity of community-acquired
pneumonia in Hong Kong
PCS 3A+
Marrie and
Huang [258]
Admission is not always
necessary for patients with
community-acquired pneumonia in
risk classes IV and V diagnosed in
the emergency room
PCS 3A+
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Myint et al. [254] Severity assessment criteria
recommended by the British
Thoracic Society (BTS) for
community-acquired pneumonia
(CAP) and older patients. Should
SOAR (systolic blood pressure,
oxygenation, age and respiratory
rate) criteria be used in older
people? A compilation study of
two prospective cohorts
PCS 3A+
Biomarkers
Chalmers
et al. [267]
Admission D-dimer can identify
low-risk patients with
community-acquired pneumonia
PCS 3A+
Christ-Crain
et al. [271]
Pro-adrenomedullin to predict
severity and outcome in
community-acquired pneumonia
PCS 3A+
Christ-Crain
et al. [274]
Free and total cortisol levels as
predictors of severity and
outcome in community-acquired
pneumonia
PCS 3B+
Christ-Crain
et al. [269]
Use of B-type natriuretic peptide in
the risk stratiﬁcation of
community-acquired pneumonia
PCS 3B+
Hirakata et al. [261] Comparison of usefulness of plasma
procalcitonin and C-reactive
protein measurements for
estimation of severity in adults
with community-acquired
pneumonia
RCS 4C)
Hohenthal
et al. [262]
Utility of C-reactive protein in
assessing the disease severity and
complications of
community-acquired pneumonia
RCS 4B+
Holm et al. [228] Procalcitonin vs. C-reactive protein
for predicting pneumonia in adults
with lower respiratory tract
infection in primary care
PCS 3B+
Huang et al. [272] Midregional proadrenomedullin as a
prognostic tool in
community-acquired pneumonia
PCS 3A+
Menendez
et al. [263]
Biomarkers improve mortality
prediction by prognostic scales in
community-acquired
pneumonia
PCS 3A+
Okimoto et al. [265] Procalcitonin and severity of
community-acquired pneumonia
RCS 4C)
Kruger et al. [266] Pro-atrial natriuretic peptide and
pro-vasopressin to predict
severity and prognosis in
community-acquired pneumonia:
results from the German
competence network CAPNETZ
PCS 3A+
Kruger et al. [276] Procalcitonin predicts patients at
low risk of death from
community-acquired pneumonia
across all CRB-65 classes
PCS 3A+
Kruger et al. [268] C-terminal provasopressin
(copeptin) in patients with
community-acquired
pneumonia—inﬂuence of antibiotic
pretreatment: results from the
German competence network
CAPNETZ
PCS 3A+
Prat et al. [270] Midregional pro-atrial natriuretic
peptide as a prognostic marker in
pneumonia
PCS 3A+
Salluh et al. [275] Adrenal response in severe
community-acquired pneumonia:
impact on outcomes and disease
severity
PCS 3A+
Tejera et al. [273] Prognosis of community-acquired
pneumonia (CAP): value of
triggering receptor expressed on
myeloid cells-1 (TREM-1) and
other mediators of the
inﬂammatory response
PCS 3B)
Thiem et al. [264] C-reactive protein, severity of
pneumonia and mortality in
elderly, hospitalised patients with
community-acquired pneumonia
RCS 4B+
Who should be considered for ICU admission?
Recommendation: Findings reﬂecting acute respiratory
failure, severe sepsis or septic shock and radiographic exten-
sion of inﬁltrates, as well as severely decompensated
co-morbities, should prompt consideration of admission to
the ICU or an intermediate care unit [A3].
The predictive potential of rules for the prediction of ICU
admission depends on local facilities. Therefore, it appears
that severity criteria should be used to indicate the need for
intensive care treatment rather than care in a special unit.
The presence of at least two of systolic blood pressure
<90 mmHg, severe respiratory failure (PaO2/FIO2 < 250),
involvement of >two lobes on chest radiograph (multilobar
involvement), or one of requirement for mechanical ventila-
tion or requirement for vasopressors >4 h (septic shock),
indicates severe CAP. Alternatively, the presence of several
minor criteria as provided in the last IDSA/ATS update may
indicate severe CAP [A3].
Both rules should increase the attention given to the rec-
ognition of patients with unstable courses of pneumonia in
order to avoid delayed transfer to the ICU.
External validation of the modiﬁed ATS rule as well as
other rules (e.g. the IDSA/ATS rule [278] and SMART-COP
rule [279,280]) has resulted in two important insights. First,
no rule is able to account for all important severity criteria,
which could justify ICU admission without substantial loss of
speciﬁcity. Second, the decision to admit to the ICU is usu-
ally not exclusively based on clinical criteria but also depends
on the local settings and facilities [279,281–283]. Therefore,
it appears that criteria for ICU admission should be used as
indicators for the need for intensiﬁed treatment (i.e. moni-
toring and treatment for acute respiratory failure and/or
severe sepsis) rather than as advice for ICU admission.
Whereas no score has been shown to be consistently
superior to others, scores relying on so-called ‘minor crite-
ria’ should be preferred, at least for clinical use, because they
avoid relying on tautological ‘major criteria’. Pneumonia
severity rules such as CRB-65/CURB-65 and PSI are not use-
ful for identifying patients with severe pneumonia.
In view of a worse prognosis in patients with a delayed
transfer to the ICU as compared with direct transfer
patients, close monitoring within intensiﬁed treatment should
be offered to patients at risk of progressive disease. How-
ever, there is still a major need for predictors of patients
who will deteriorate. The recently developed REA-ICU index
still awaits validation in independent cohorts and different
settings [284]. Currently, close monitoring of patients at risk
within intensiﬁed treatment is the best measure to identify
those patients.
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Consecutive measurements of CRP and assessment of
oxygenation may be used during follow-up to assess treat-
ment response [285,286].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Brown et al. [281] Validation of the Infectious Disease
Society of America/American Thoracic
Society 2007 guidelines for severe
community-acquired pneumonia
PCS 3B+
Bruns et al. [285] Usefulness of consecutive C-reactive
protein measurements in follow-up
of severe community-acquired
pneumonia
PCS 3B+
Charles et al. [279] SMART-COP: a tool for predicting the
need for intensive respiratory or
vasopressor support in
community-acquired pneumonia
PCS 3A+
Marrie and
Shariatzadeh [282]
Community-acquired pneumonia
requiring admission to an intensive
care unit: a descriptive study
RCS 4A+
Phua et al. [278] Validation and clinical implications of
the IDSA/ATS minor criteria for
severe community-acquired pneumonia
PCS 3A+
Renaud et al. [284] Association between timing of intensive
care unit admission and outcomes
for emergency department patients
with community-acquired pneumonia
PCS 3A+
Wu et al. [286] Early evolution of arterial oxygenation
in severe community-acquired
pneumonia: a prospective
observational study
PCS 3B)
What is the value of blood cultures in the diagnosis of commu-
nity-acquired pneumonia?
Recommendation: Two sets of blood cultures should be
performed in all patients with CAP who require hospitaliza-
tion [A3].
New information. Recommendation not changed.
S. pneumoniae is identiﬁed in approximately 60% of positive
blood cultures [287,288] and Haemophilus inﬂuenzae in vari-
ous percentages from 2% to 13%. Other organisms are
recovered in diminishing order of frequency from 14% to 2%
and 1%: Gram-negative aerobes, streptococci (S. pyogenes and
other), Staphylococcus aureus and mixtures of organisms [287].
For most of the latter it is difﬁcult to decide whether they
were present in the bloodstream or are skin contaminants.
In a retrospective observational cohort study of 684
hospitalized patients admitted via the Emergency Department
for treatment of pneumonia [289], only 3.4% had true
positive blood cultures. Combining the results of this study
with six other studies, only 2.2% of >3000 patients had anti-
biotics changed based on positive blood cultures. This study
demonstrates the limited utility of blood cultures in CAP
patients. However, it did not include many patients at risk of
multidrug-resistant pathogens.
From a systematic review of 15 studies with a total of
3898 adult patients admitted with CAP, it was concluded
that blood cultures rarely alter empirical antibiotic therapy,
and even when there is a change, it is mostly not likely to
impact patient outcome [290]. The ﬁndings of this systematic
review do not support obtaining blood cultures in all adults
hospitalized with CAP.
However, also in this systematic review, most investiga-
tions excluded immunocompromized or other high-risk
groups, which could have biased results against blood culture
utility. It would be prudent therefore not to generalize the
ﬁndings.
In addition, all 15 studies included in this review were
observational. Most did not prospectively require blood cul-
tures in all patients admitted with CAP. Several studies did
not explicitly require two sets of blood cultures or that
blood cultures be done prior to antibiotics, so they may not
have revealed the maximum utility of blood cultures. Methici-
lin-resistant Staphylococcus aureus (MRSA) previously conﬁned
to nosocomial infections has become more prevalent in the
community, causing community-associated MRSA infections,
including CAP [61,291]. During recent years healthy young
people without traditional risk factors for S. aureus disease
present increasingly with severe MRSA CAP associated with
high mortality. Many strains contain toxin and Panton-Valen-
tine leucocidine genes. Specimens including blood cultures
should be obtained for diagnostic and antimicrobial drug sus-
ceptibility testing in order to target therapy.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Bradley [291] Role of Staphylococcus aureus in CAP MA 1A+
Hageman
et al. [61]
Role of Staphylococcus aureus in CAP RCS 4A+
Beneson
et al. [289]
Selective use of blood cultures in emergency
department pneumonia patients
RCS 4A+
Asfhar
et al. [290]
Blood cultures for community-acquired
pneumonia: are they worthy of two quality
measures? A systematic review
SR 1A+
What other invasive techniques for normally sterile specimens can
be useful in the laboratory diagnosis of pneumonia?
Recommendation: (a) Thoracentesis: diagnostic thoracente-
sis should be performed in hospitalized patients with CAP
when a signiﬁcant pleural effusion is present [A3].
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No new information. Recommendation not changed.
(b) Transthoracic needle aspiration (TNA): because of the
inherent potential adverse effects, TNA can be considered
ONLY on an individual basis for some severely ill patients
with a focal inﬁltrate in whom less invasive measures have
been non-diagnostic [A3].
No new information. Recommendation not changed.
(c) Bronchoscopic protected specimen brush (PSB) and bronc-
hoalveolar lavage (BAL)) and quantitative endotracheal aspirates
(QEA): BAL should be the preferred technique in non-resolv-
ing pneumonia [A3].
Bronchoscopic sampling of the lower respiratory tract can
be considered in intubated patients and selected non-intubat-
ed patients, where gas exchange status allows [A3].
New information. Recommendation not changed.
El Sohl studied nursing home patients requiring mechanical
ventilation for suspected pneumonia and evaluated quantita-
tive endotracheal aspirates in comparison with PSB and BAL
specimens [292]. This study shows that QEA correlate well
with quantitative bronchoscopic PSB and BAL. Diagnostic
accuracy was most favourable at 104 CFU/mL and may be a
reliable alternative to PSB or BAL in patients admitted from
nursing homes requiring ventilation when bronchoscopic
procedures are not feasible or available.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
El Sohl
et al. [292]
Diagnostic yield of quantitative endotracheal
aspirates in patients with severe nursing
home-acquired pneumonia
PCS 3A+
What is the value of sputum examination?
Recommendation: Gram strain: should be performed when
a purulent sputum sample can be obtained from patients
with CAP and processed in a timely manner. The presence
of a predominant bacterial morphotype allows inference of
the aetiologic bacterial species and interpretation of the
results of sputum culture [A3].
New information. Recommendation not changed.
Acceptable sputum specimens can be obtained with some
effort from approximately 25% of patients after inhalation of
hypertonic saline to induce secretion and cough [293].
The value of the Gram stain of acceptable sputum speci-
mens depends on the presence of a predominant bacterial
morphotype [294–296]. In a retrospective cohort study
[297], sputum examination was used as a diagnostic tool in a
minority of the patients, without noticeable beneﬁt in the
clinical management of CAP inpatients.
The study of Anevlavis is the ﬁrst reported study to have
such an amount of information concerning operating charac-
teristics and the diagnostic value of sputum Gram stain in
1390 patients with bacteraemic CAP [298]. The sensitivity of
sputum Gram stain was 82% for pneumococcal pneumonia,
76% for staphylococcal pneumonia and 79% for Haemophilus
inﬂuenzae pneumonia, with speciﬁcities ranging from 93% to
96%. Data from this study suggest that a properly collected
and read Gram stain provides a simple, readily available,
rapid and inexpensive test result and can be a dependable
test for the early aetiological diagnosis of bacterial pneumo-
nia in bacteraemic patients.
Infection by Aspergillus spp. can be distinguished from col-
onization by the presence of hyphae in respiratory specimens
but the diagnosis of aspergillosis is still based on the detec-
tion of circulating antigens in serum [299].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study. CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Lagerstrom
et al. [293]
Good quality sputum specimens can
be obtained after inhalation of
hypertonic saline
PCS 3A+
Garcia Vazquez
et al. [294]
The value of the presence of predominant
morphotype in sputum for aetiological
diagnosis of CAP conﬁrmed
PCS 3A+
Van der Eerden
et al. [295]
The value of the presence of
predominant morphotype in sputum
for aetiological diagnosis of CAP
conﬁrmed
PCS 3A+
Musher et al. [296] The value of the presence of predominant
morphotype in sputum for aetiological
diagnosis of CAP conﬁrmed
PCS 3A+
Uffredi et al. [299] Diagnosis of aspergillus CAP in sputum RCS 4B+
Signori et al. [297] Sputum examination in the clinical
management of community-acquired
pneumonia
RCS 4A+
Anevlavis
et al. [298]
A prospective study of the diagnostic
utility of sputum Gram stain in pneumonia
PCS 3A+
Recommendation: Culture: a culture from a purulent
sputum specimen of a bacterial species compatible with the
morphotype observed in the Gram stain, which is processed
correctly, should be considered for conﬁrmation of the spe-
cies identiﬁcation and antibiotic susceptibility testing [B3].
No new information. Recommendation not changed.
Sensitivity and speciﬁcity of sputum cultures are reduced
by contamination with ﬂora colonizing the upper respiratory
tract. The value of sputum cultures in establishing a bacterial
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cause of LRTI depends on how the specimens are collected
and processed and on whether a predominant bacterial mor-
photype has been observed in the Gram stain.
What can antigen tests offer in the diagnosis of community-
acquired pneumonia?
Recommendation: The immunochromatographic urinary
antigen test for S. pneumoniae should be performed in
patients admitted to the hospital for reasons of illness sever-
ity. This test should also be considered whenever a pleural
ﬂuid sample is obtained in the setting of a parapneumonic
effusion [A3].
Urine L. pneumophila serogroup 1 antigen detection should
be performed in patients admitted to the hospital for rea-
sons of severity and in other patients where this infection is
clinically or epidemiologically suspected [A3]. L. pneumophila
serogroup 1 antigen detection in urine is the most rapid
method for diagnosing or excluding the infection. A negative
test makes legionella unlikely, but does not exclude legionella
infection [A3].
The value of the S. pneumoniae urinary antigen test in
adults has a sensitivity of 65–100% and a speciﬁcity of 94%;
however, weak positive results should be interpreted with
caution. There is a relationship between the degree of the
S. pneumoniae urinary antigen test positivity and the pneu-
monic severity index [300]. Therefore and for cost saving,
the test could be applied in a sequential manner with
reservation of the test for high-risk patients for whom
demonstrative results of a sputum Gram stain are unavailable
[301–310]. An S. pneumoniae type speciﬁc urinary antigen
identiﬁes the serotype involved [311].
Also in the prospective cohort study reported by Kobashi
the pneumococcal urinary immunochromatographic test
(ICT) [312] increased the diagnostic yield for pneumococcal
pneumonia in patients with CAP and was particularly useful
for diagnosing patients with poor quality sputum in whom
antibiotic treatment nevertheless had to be selected. In this
study, the authors were able to establish the clinical impact
of the rapidity and simplicity of the ICT test for pneumococ-
cal pneumonia. Pneumonia caused by S. pneumoniae also
appeared to be treated safely and effectively with high-dose
penicillin based on positive results of the urinary antigen test
in the retrospective study reported by Oka [313]. Even
compared with PCR on blood samples the Binax NOW
S. pneumonia urinary antigen test is a more sensitive and
rapid test for the early diagnosis of bacteraemic pneumococ-
cal pneumonia [314]. Persistence of S. pneumoniae antigenu-
ria following diagnosis of pneumococcal pneumonia is
normal and can be prolonged, especially if concentrated
urine is used [315].
The effect of pretreatment with antibiotics resulted in
contradictory reports: a lower detection rate in one study
[295] and an increased detection rate if the test is
performed 24–48 h after initiation of antibiotic treatment
[316]. The urinary antigen test may also be carried out on
pleural ﬂuid with a sensitivity and speciﬁcity of 79% and 94%,
respectively [307], and on serum samples with a sensitivity
of 50% in bacteraemic patients and 40% in non-bacteraemic
patients [317]. The ICT test performed on pleural ﬂuid sam-
ples augments the standard diagnostic methods of blood and
pleural ﬂuid cultures, even in the case of prior antibiotic
therapy, and enhances the ICT urinary antigen test: it may
provide additional information beyond that obtained by the
measurement of urine samples alone and vice versa [318].
Therefore this test should be considered whenever a pleural
ﬂuid sample is obtained in the setting of a parapneumonic
effusion, particularly when the urinary antigen test is not
contributory.
Vaccination does not result in a positive urinary antigen
test [161]. Urinary antigen detection is currently the most
helpful rapid test for the diagnosis of Legionella infection.
The immunochromatographic format is better suited for sin-
gle specimens, and produces a result within minutes. In one
report different urinary antigen tests have an identical sensi-
tivity [319]; in a second report the results of the tests differ
when performed on unconcentrated urine samples but are
identical when performed on concentrated urine specimens
[320]. In the study by Olsen, the Binax test had a signiﬁcantly
higher sensitivity than the Biotest kit both for L. pneumophila
serogroup one species and for non-L. pneumophila species or
non-serogroup 1 L. pneumophila [321]. New Legionella anti-
gen tests have been developed and are becoming available.
They show performances comparable to that of the Binax
NOW test and could be an alternative for the detection of
L. pneumophila antigen in urine from patients suspected of
having a Legionella pneumonia [322,323].
Since the urinary antigen test has been introduced, early
diagnosis and treatment has helped to improve the outcomes
and case fatality rate of cases involved in outbreaks of Legio-
nellosis [324].
In Legionella infection there also exists a relationship
between the degree of positivity of the urinary antigen test
and the severity of the disease [325]. A positive result of the
urinary antigen test, as demonstrated in the CAPNETZ study
[326], is associated with a more severe clinical course and
leads to a potential relevant under-recognition of species
other than L. pneumophila.
Rapid antigen tests on respiratory specimens for the diag-
nosis of inﬂuenza virus infection in adult patients are too
insensitive and consequently of limited value for conﬁrming
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the diagnosis when inﬂuenza is clinically suspected in adults,
according to one study [327].
However, the study by Falsey [328] clearly showed that
rapid inﬂuenza testing leads to reduction in antibiotic use in
hospitalized adults.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study. CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Gutierrez
et al. [301]
Value of S. pneumoniae urinary antigen
test (UAT)
PCS 3B+
Smith et al. [302] Value of S. pneumoniae UAT PCS 3A+
Marcos
et al. [303]
Value of S. pneumoniae UAT PCS 3A+
Roson
et al. [304]
Value of S. pneumoniae UAT. Proposal
to apply S. pneumoniae UAT in
high-risk patients without
demonstrative Gram stain result
PCS 3A+
Ishida et al. [305] Value of S. pneumoniae UAT PCS 3A+
Stralin
et al. [306]
Value of S. pneumoniae UAT PCS 3A+
Andreo
et al. [307]
Value of S. pneumoniae UAT PCS 3A+
Ercis et al. [308] Value of S. pneumoniae UAT PCS 3A+
Genne et al. [309] Value of S. pneumoniae UAT PCS 3A+
Lasocki
et al. [310]
Value of S. pneumoniae UAT RCS 4A+
Leeming
et al. [311]
S. pneumoniae serotype speciﬁc
EIA on urine sample
PCS 3A+
Van der Eerden
et al. [295]
Value of S. pneumoniae UAT PCS 3A+
Korsgaard
et al. [316]
S. pneumoniae UAT more positive
after antibiotic treatment
PCS 3A+
Andreo
et al. [307]
S. pneumoniae UAT applicable on BAL PCS 3A+
Dominguez
et al. [317]
S. pneumoniae UAT applied on serum PCS 3A+
Ortega
et al. [300]
Relation between UAT and PSI PCS 3A+
Vazquez
et al. [329]
S. pneumoniae UAT not positive after
S. pneumoniae vaccination
PCS 3A+
Dirven et al. [319] Sensitivity of three UATs similar PCS 3A+
Guerrero
et al. [320]
Sensitivity of UATs different on
unconcentrated samples, identical on
concentrated samples
PCS 3A+
Blazques
et al. [325]
Positivity of Legionella UAT related
to severity of disease
PCS 3A+
Kobashi
et al. [312]
Evaluating the use of a Streptococcus
pneumoniae urinary antigen detection
kit for the management of
community-acquired pneumonia in Japan
PCS 3A+
Oka et al. [313] The efﬁcacy of high-dose penicillin for
community-acquired pneumonia
diagnosed by pneumococcal urine
antigen test
RCS 4A+
Smith
et al. [314]
Diagnosis of Streptococcus pneumoniae
infections in adults with bacteraemia and
community-acquired pneumonia: clinical
comparison of pneumococcal PCR and
urinary antigen detection
PCS 3A+
Andreo
et al. [315]
Persistence of Streptococcus pneumoniae
urinary antigen excretion after
pneumococcal pneumonia
PCS 3A+
Porcel
et al. [318]
Contribution of a pleural antigen assay
(Binax NOW) to the diagnosis of
pneumococcal pneumonia
PCS 4A+
Olsen
et al. [321]
Comparison of the sensitivity of the
Legionella urinary antigen EIA kits
from Binax and Biotest with urine
from patients with infections caused by
less common serogroups and subgroups
of Legionella
RCS 4A+
Blanco
et al. [322]
Detection of Legionella antigen in
non-concentrated and concentrated
urine samples by a new
immunochromatographic assay
RCS 4A+
Diederen
et al. [323]
Evaluation of the Oxoid Xpect
Legionella test kit for detection of
Legionella pneumophila serogroup
1 antigen in urine
RCS 4A+
Alvarez
et al. [324]
Impact of the Legionella urinary antigen
test on epidemiological trends in
community outbreaks of legionellosis
in Catalonia, Spain, 1990–2004
PCS 3A+
Von Baum
et al. [326]
Community-acquired Legionella pneumonia:
new insights from the German competence
network for community acquired
pneumonia
PCS 3A+
Steininger
et al. [327]
Near-patient assays for diagnosis of
inﬂuenza virus infection in adult
patients
RCS 4A+
Falsey [328] Impact of rapid diagnosis on
management of adults hospitalized
with inﬂuenza
RCS 4A+
What can serological tests offer in the diagnosis of pneumonia?
Recommendation: Serology for infections caused by
M. pneumoniae, C. pneumoniae and Legionella is more useful in
epidemiological studies than in the routine management of
the individual patient. If aetiological diagnosis of the atypical
agents is considered in the management of the individual
patient (e.g. in patients not responding to betalactam
therapy), serological tests should not be performed as the
only routine diagnostic test [A3]. A combination of IgM
antibody detection and PCR may be the most sensitive
approach [A3].
Many test formats for the detection of Mycoplasma pneu-
moniae, Chlamydophila pneumonia and Legionella pneumophila
antibodies have been proposed. Several studies illustrate a
lack of standardization of antigens of Mycoplasma pneumo-
niae [330–332]. In one study 6/12 and 9/12 of PCR-docu-
mented M. pneumoniae infections were diagnosed in acute
and convalescent phase sera, respectively [333]. In another
study anti-M. pneumoniae IgM antibodies were detected in
7–25% (depending on the test applied) of acute sera and
IgG antibodies in 41–63% of convalescent sera [330].
Although IgM detection in the acute phase shows a moder-
ate sensitivity, provided a speciﬁc test is used, a combina-
tion of IgM antibody detection and PCR may be the most
sensitive approach to diagnose Mycoplasma pneumoniae
infections, as demonstrated in the study by Martinez [334]
and in the CAPNETZ study [335]. Also for acute LRTI due
to C. pneumoniae a combination of PCR detection and spe-
ciﬁc single serum IgM measurement seems recommended
[336].
Also the recent study on Legionella antibody detection
conﬁrms that the diagnosis cannot be based on one serum
sample from the patient. As serology based on paired sera in
most cases cannot be conﬁrmed until rather late in the
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course of the disease, it is advisable to use other diagnostic
tests in combination with serology [337].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study. CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Beersma
et al. [330]
Lack of standardization of antigens for
M. pneumoniae serology of CAP. Variations
in antibody detection depending on
test applied
PCS 3A+
Talkington
et al. [331]
Lack of standardization of antigens for
M. pneumoniae serology of CAP
PCS 3A+
Templeton
et al. [333]
Serology detects 50% and 66.6% of cases in
acute and convalescent phases, respectively
PCS 3A+
Nir-Paz
et al. [332]
Lack of standardization of antigens
for M. pneumoniae serology of CAP
PCS 3A+
Martinez
et al. [334]
Detection of Mycoplasma pneumoniae in
adult community-acquired pneumonia
by PCR and serology
PCS 3A+
Von Baum
et al. [335]
Mycoplasma pneumoniae pneumonia revisited
within the German Competence Network
for Community-acquired pneumonia
(CAPNETZ)
PCS 3A+
Hvidsten
et al. [336]
Chlamydophila pneumoniae diagnostics:
importance of methodology in relation
to timing of sampling
RCS 4A+
Elverdal
et al. [337]
Comparison and evaluation of four
commercial kits relative to an in-house
immunoﬂuorescence test for detection
of antibodies against Legionella pneumophila
RCS 4A+
Are ampliﬁcation tests useful for the diagnosis of LRTI?
Recommendation: Where available, application of quanti-
tative molecular tests for the detection of Streptococcus pneu-
moniae, both in sputum and in blood, may be valuable in
CAP patients in whom antibiotic therapy has been initiated
and may be a useful tool for severity assessment Application
of molecular tests for the detection of inﬂuenza and RSV
should be considered during the winter season and for the
detection of atypical pathogens, provided the tests are vali-
dated and the results can be obtained sufﬁciently rapidly to
be therapeutically relevant [A3].
Qualitative Nucleic Acid Ampliﬁcation Tests (NAATs) for
S. pneumoniae on pleural ﬂuid, peripheral blood or sputum
add little to the existing diagnostic tests in sputum and are
unable to distinguish colonization from infection.
In a recent prospective study, real-time quantitative PCR
(RQ-PCR) was evaluated on sputum samples from patients
with CAP admitted to the hospital: the yield from RQ-PCR
was almost twice as high as that from sputum culture in
patients with proven pneumococcal aetiology. These ﬁgures
suggest that in hospital-treated CAP patients, sputum PCR is
a more sensitive method for detecting S. pneumoniae than
sputum culture and the previously chosen cut-off level
corresponding to 105 CFU/mL is conﬁrmed [338]. Especially
when antibiotic treatment has been initiated, RQ-PCR,
together with urine antigen detection, was the best method
for identifying S. pneumoniae.
The detection of S. pneumoniae speciﬁc targets by real-time
PCR assays, such as Spn9802 or lytA in plasma, is also useful
for the rapid detection of bacteraemic pneumococcal pneu-
monia [339]. Detection of bacterial DNA load in whole blood
supports the diagnosis of S. pneumoniae infection in patients
with CAP [340]. Bacterial load is associated with the likeli-
hood of death, the risk of septic shock, and the need for
mechanical ventilation. High genomic bacterial load for S. pneu-
moniae may be a useful tool for severity assessment [341].
The ompP6-based real-time PCR for the detection of
Haemophilus inﬂuenzae is both sensitive and speciﬁc for the
detection of Haemophilus inﬂuenzae in respiratory secretions.
Quantiﬁcation facilitates discrimination between disease-caus-
ing H. inﬂuenzae strains and commensal colonization [342].
Quantitative PCR assays have also been shown to be use-
ful in the diagnosis of CAP cases caused by L. pneumophila,
although they had lower sensitivity than the urinary antigen
test. Both RQ-PCR and antigen testing should be considered
complementary in the diagnostic armamentarium for Legio-
nellosis. High bacterial loads determined by RQ-PCR in LRT
samples were useful for predicting disease severity, which
may be an advantage of these techniques and therefore war-
rant further investigation [343].
NAATs for M. pneumoniae, C. pneumoniae, L. pneumophila
and B. pertussis, preferably in sputum, have been further vali-
dated [333,344].
The addition of an L. pneumophila-speciﬁc PCR to a uri-
nary antigen test is useful in patients with suspected Legion-
naires’ disease who produce sputum and might allow the
early detection of a signiﬁcant number of additional patients
[345].
For the detection of M. pneumoniae CAP or LRTI cases,
PCR was less sensitive than serology in one study [334] but
superior to serology, especially during the early phases of
infection, in another study [346]. Data analysis of different
studies indicates that no single available test was reliable for
the identiﬁcation of M. pneumoniae in CAP. A combination of
serology and PCR proved to be the most reliable approach
for identiﬁcation of M. pneumoniae [334,335,347].
Also for acute LRTI caused by C. pneumoniae a combina-
tion of PCR detection and speciﬁc single serum IgM
measurement seems recommended [336].
The use of a Bordetella pertussis speciﬁc PCR in combina-
tion with single-serum serology [348] or the combination of
culture and PCR increases the sensitivity for pertussis diag-
nosis [349].
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The results of a recent study conﬁrm previous ﬁndings
that the addition of PCR-based methods to the conventional
microbial techniques improves the yield of aetiological agents
signiﬁcantly and indicate that PCR is not only more rapid
than conventional methods, but also more sensitive, both in
aetiological diagnosis of CAP [18] and for the detection of
respiratory viruses in LRTI [350–353], allowing clinicians to
initiate optimal symptomatic treatment and rational use of
antibiotics, adequate antiviral therapy where indicated and
optimal infection control.
Previously unknown viruses have been discovered: several
coronaviruses, human metapneumovirus and bocavirus. They
are detected in CAP by NAATs. Reports on infection by a
mixture of several viruses or infection by a mixture of
viruses and bacteria exist. Systematic comprehensive studies
are awaited to deﬁne the clinical importance of these viral
and mixed infections.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Templeton
et al. [333]
AT for M. pneumoniae and Bordetella
pertussis validated
PCS 3A+
Raty et al. [344] AT for M. pneumoniae validated PCS 3A+
Johansson
et al. [338]
Quantitative detection of Streptococcus
pneumoniae from sputum samples with
real-time quantitative polymerase chain
reaction for aetiological diagnosis of
community-acquired pneumonia
PCS 3A+
Abdeldaim
et al. [339]
Usefulness of real-time PCR for lytA,
ply and Spn9802 on plasma samples for
the diagnosis of pneumococcal
pneumonia
PCS 3A+
Peters
et al. [340]
Streptococcus pneumoniae DNA load in blood
as a marker of infection in patients with
community-acquired pneumonia
RCS 4A+
Rello et al. [341] Severity of pneumococcal pneumonia
associated with genomic bacterial load
PCS 3A+
Abdeldaim
et al. [342]
Detection of Haemophilus inﬂuenzae in
respiratory secretions from
pneumonia patients by quantitative
real-time polymerase chain reaction
PCS 3A+
Maurin
et al. [343]
Quantitative real-time PCR tests for
diagnostic and prognostic purposes in
cases of legionellosis
RCS 4A+
Diederen
et al. [345]
Utility of real-time PCR for diagnosis of
Legionnaires’ disease in routine clinical
practice
RCS 4A+
Martinez
et al. [334]
Detection of Mycoplasma pneumoniae
in adult community-acquired pneumonia
by PCR and serology
PCS 3A+
Nilsson
et al. [346]
Polymerase chain reaction is superior
to serology for the diagnosis of acute
Mycoplasma pneumoniae infection and
reveals a high rate of persistent
infection
PCS 3A+
Thurman
et al. [347]
Comparison of laboratory diagnostic
procedures for detection of Mycoplasma
pneumoniae in community outbreaks
PCS 3A+
Von Baum
et al. [335]
Mycoplasma pneumoniae pneumonia revisited
within the German Competence Network
for Community-acquired pneumonia
(CAPNETZ). BMC Infect Dis 9:62
PCS 3A+
Hvidsten
et al. [336]
Chlamydophila pneumoniae diagnostics:
importance of methodology in relation
to timing of sampling. Clin Microbiol
Infect 15:42–49
RCS 4A+
Andre´
et al. [348]
Comparison of serological and real-time
PCR assays to diagnose Bordetella pertussis
infection
PCS 3A+
Sotir
et al. [349]
Evaluation of polymerase chain reaction and
culture for diagnosis of pertussis in the
control of a county-wide outbreak focused
on adolescents and adults
PCS 3A+
Johansson
et al. [18]
Aetiology of community-acquired
pneumonia: increased microbiological
yield with new diagnostic methods
PCS 3A+
Mahony
et al. [350]
Development of a respiratory virus panel
test for detection of 20 human respiratory
viruses by use of multiplex PCR and a
ﬂuid microbead-based assay
PCS 3A+
Van de Pol
et al. [351]
Increased detection of respiratory syncytial
virus, inﬂuenza viruses, parainﬂuenza
viruses and adenoviruses with real-time
PCR in samples from patients with
respiratory symptoms
PCS 3A+
Ginocchio
et al. [352]
Evaluation of multiple test methods for the
detection of the novel 2009 inﬂuenza A
(H1N1) during the New York City
outbreak
RCS 4A+
Caram
et al. [353]
Respiratory syncytial virus outbreak in a
long-term care facility detected using
reverse transcriptase polymerase chain
reaction: an argument for real-time
detection methods
PCS 3A+
What classiﬁcation should be used for treatment?
Recommendation: Antimicrobial treatment has to be
empirical and should follow an approach according to the
individual risk of mortality. The assessment of severity
according to mild, moderate and severe pneumonia implies a
decision about the most appropriate treatment setting
(ambulatory, hospital ward or ICU) [A4]. Antimicrobial treat-
ment should be initiated as soon as possible [A3].
The guidance for empirical initial antimicrobial treatment
should follow three basic considerations and overall ten cri-
teria.
(A) Prognostic assessment
(1) The assessment of age: patients aged ‡65 years are
subdivided into those with moderate/good ability and those
who are severely disabled. Ideally, this assessment should fol-
low an established score (e.g. ADL score). Roughly, severely
disabled patients may be deﬁned as bedridden.
(2) The assessment of general prognosis: patients with
pneumonia as an expected terminal event of severe co-mor-
bidity should be managed along principles of palliative
medicine.
(B) Assessment of correct grouping
(3) Previous hospitalizations and antimicrobial treatment:
patients with hospitalizations <3 months ago and those
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with repeated recent antimicrobial treatments should be
classiﬁed as nosocomial pneumonia and treated accord-
ingly.
(4) Risk factors for severe immunosuppression (i.e. at risk
of opportunistic pathogens): these patients should be man-
aged following the guidelines for immunocompromised
patients.
(C) Assessment of factors determining selection of antimi-
crobial treatment.
(5) Severity: although severity has only a minor impact on
microbial patterns, broad combination treatment is manda-
tory in order to cover all potential pathogens and prevent
excess mortality due to treatment failure.
(6) Co-morbidity: co-morbidities may have an independent
bearing on potential underlying pathogens.
(7) Residence: nursing home residence as such may not
alter microbial patterns. Such risk should be assessed individ-
ually.
(8) Aspiration: may be witnessed or suspected; may corre-
spond to gross or silent aspiration.
(9) Regional and local patterns of microbial prevalence
and resistance.
(10) Considerations of tolerability and toxicity of antimi-
crobial agents in the individual patient.
When should antibiotics be administered after diagnosis of pneu-
monia?
Recommendation: Antibiotic treatment should be initiated
immediately after diagnosis of CAP [C3]. In patients with
CAP and septic shock, delay must not be more than 1 h
after diagnosis [A1].
As a consequence of studies suggesting an adverse prog-
nostic effect of delayed antimicrobial treatment, immediate
timely administration of antibiotics has been advocated in
patients with CAP and suggested as an indicator of quality.
Although early antibiotic treatment has been conﬁrmed as
advantageous by some authors [354], it has been heavily
challenged. Some studies failed to conﬁrm such a disadvan-
tage of delayed antibiotic treatment [355,356]; others have
questioned this practice in view of the questionable feasibility
of such a policy [357], a high rate of misdiagnosis and over-
treatment [358,359]. The American Academy of Emergency
Medicine recommended that measurement of time to ﬁrst
antibiotic dose in CAP be discontinued [360]. Not all
authors conﬁrm misdiagnosis and overtreatment along with
reporting antibiotic timing [358].
A distinct diagnosis of pneumonia seems mandatory
before initiation of antibiotic treatment. It appears that the
prognostic relevance of antibiotic timing is highest in patients
at a higher risk of death.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Berjohn
et al. [354]
Treatment and outcomes for patients with
bacteraemic pneumococcal pneumonia.
Medicine
PCS 3A+
Bruns
et al. [356]
Time to ﬁrst antibiotic related to composite
endpoint of clinical instability, ICU
admission and death
RCS 4B)
Fee and
Weber [357]
Identiﬁcation of 90% of patients ultimately
diagnosed with community-acquired
pneumonia within 4 h of emergency
department arrival may not be feasible
RCS 4C)
Kanwar
et al. [359]
Misdiagnosis of community-acquired
pneumonia and inappropriate utilization of
antibiotics: side-effects of the 4-h antibiotic
administration rule
PCS 3B)
Cheng and
Buising [355]
Delayed administration of antibiotics and
mortality in patients with
community-acquired pneumonia
PCS 3A+
Friedberg
et al. [358]
Reporting hospitals’ antibiotic timing in
pneumonia: adverse consequences
for patients?
RCS 4A+
Pines
et al. [360]
The measurement of time to ﬁrst antibiotic
dose for pneumonia in the emergency
department: a white paper and position
statement prepared for the American
Academy of Emergency Medicine
Expert
opinion
6C?
What initial empirical treatments are recommended? Treatment
options for hospitalized patients with community-acquired pneu-
monia (no need for intensive care treatment) (in alphabetical
order) [C4]:
Recommendation:
Aminopenicillin ± macrolidea,b
Aminopenicillin/b-lactamase inhibitora ± macrolideb
Non-antipseudomonal cephalosporin
Cefotaxime or ceftriaxone ± macrolideb
Levoﬂoxacina
Moxiﬂoxacina,c
Penicillin G ± macrolide
aCan be applied as sequential treatment using the same drug.
bNew macrolides preferred to erythromycin.
cWithin the ﬂuoroquinolones, moxiﬂoxacin has the highest
antipneumococcal activity.
In patients at risk of GNEB, particularly strains with ESBL, but without
risk (or after exclusion of) of P. aeruginosa, ertapenem may be used.
Several publications have demonstrated that low-level
pneumococcal resistance to penicillin is not associated with
adverse outcomes in the treatment of patients with commu-
nity-acquired pneumonia. Resistance to macrolides may be
relevant in patients with moderate to severe pneumonia
[361,362]. Therefore, the choice of antimicrobial agents
should be based on considerations of allergy, intolerance,
previous use of penicillins, macrolides or quinolones, cost
and potential adverse effects rather than pencillin resistance.
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Several retrospective studies suggest the superiority of a
b-lactam-macrolide combination therapy in hospitalized
patients, particularly those with more severe disease [363–
365]. However, deﬁnite conclusions cannot be made from
the present data [366]. Therefore, it appears that combina-
tion treatment should be restricted to patients with higher
risk classes. As a rule of thumb, the more severely the
patient presents, the stronger is the recommendation for
such combination treatment.
There is a new formulation of amoxicillin-clavulanic acid
available (2000/125 instead of 875–1000/125), which offers
the advantage of higher penicillin dosing [187,367–369].
This may be particularly advantageous in patients with
pneumococcal pneumonia resistant (low-level) to penicillin
[187].
Respiratory quinolones are now established treatment
options [363,370–379]. However, the potential small
superiority of respiratory quinolones as compared with
penicillin and macrolides must be balanced against concerns
of selection pressure and cost [374]. Of note, because of
the absence of pneumococcal coverage, ciproﬂoxacin is
contraindicated in the treatment of community-acquired
pneumonia.
The EMEA has limited the use of oral moxiﬂoxacin.
Although it was stated that ‘the beneﬁts continue to
outweigh its risks’, it is stated that it should only be
prescribed when other antibiotics cannot be used or have
failed. This recommendation was made mainly in view of an
increased risk of adverse hepatic reactions. There is no
evidence from the literature that moxiﬂoxacin should be
considered differently to levoﬂoxacin in this regard.
Moreover, there is evidence that liver toxicity is higher in
amoxicillin-clavulanic acid than in respiratory quinolones
[380].
Two additional agents have been investigated in patients
with CAP: tigecycline [370,376,377,381] and ertapenem
[382–384]. However, there are concerns about low serum
levels of tigecycline at standard dosage, which might be
hazardous in bacteraemic pneumonia. Ertapenem seems to
be an attractive choice in patients at risk of Gram-negative
enterobacteriaceae (GNEB) infection, particularly with ESBL-
producing strains, but not in those at risk of Pseudomonas
aeruginosa infection [385–388].
Regular coverage of atypical pathogens may not be neces-
sary in non-severe hospitalized patients [244,389–391].
Treatment options for patients with severe community-acquired
pneumonia [c4] (ICU or intermediate care):
Recommendation:
No risk factors for P. aeruginosa
Non-antipseudomonal cephalosporin III + macrolidea
or
moxiﬂoxacin or levoﬂoxacin ± non-antipseudomonal cephalosporin III
Risk factors for P. aeruginosa
Antipseudomonal cephalosporinb or acylureidopenicillin/b-lactamase
inhibitor or carbapenem (meropenem preferred, up to 6 g possible,
3 · 2 in 3-h infusion)
PLUS
Ciproﬂoxacinc OR
PLUS
Macrolidea + aminoglycoside (gentamicin, tobramycin or amikacin)
aNew macrolides preferred to erythromycin.
bCeftazidime has to be combined with penicillin G for coverage of
S. pneumoniae.
cLevoﬂoxacin 750 mg/24 h or 500 mg twice daily is an alternative and
also covers Gram-positive bacteria if treatment is empirical.
No controlled trials are available for patients treated in
the ICU or meeting predictive rules for severe CAP.
Combination treatment offers an advantage over mono-
therapy by expanding the antimicrobial coverage [392–394]
and probably by immunomodulation (macrolides, quinol-
ones). Therefore, it should be the treatment of choice. How-
ever, respiratory quinolones may be used as monotherapy in
severe pneumonia without septic shock [395–401].
The incidence of CAP through P. aeruginosa seems to be
low [388]. In patients with risk factors for P. aeruginosa, me-
ropenem offers advantages over imipenem because of the
option to increase the dose signiﬁcantly up to 3 · 2 g [402].
Patients at risk of CAP through P. aeruginosa always should
be treated by two antipseudomonal drugs in order to reduce
the chance of inadequate treatment. After pathogen isolation
and susceptibility testing, combination treatment may be de-
escalated to monotherapy.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Alvarez-Lerma
[395]
Levoﬂoxacin in the treatment of
pneumonia in intensive care unit patients
RCS 4B+
Erard
et al. [396]
Full-course oral levoﬂoxacin for
treatment of hospitalized patients
with community-acquired pneumonia
RCT 2A+
Van Bambeke
and Tulkens [380]
Safety proﬁle of the respiratory
ﬂuoroquinolone moxiﬂoxacin: comparison
with other ﬂuoroquinolones and
other antibacterial classes
MA 1A+
Frei et al. [389] Impact of atypical coverage for patients
with community-acquired pneumonia
managed on the medical ward: results from
the United States Community-Acquired
Pneumonia Project
RCS 4A+
Mills et al. [244] Effectiveness of beta lactam antibiotics
compared with antibiotics active against
atypical pathogens in non-severe
community-acquired pneumonia:
meta-analysis
MA 1A+
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Portier
et al. [372]
Moxiﬂoxacin monotherapy compared with
amoxicillin-clavulanate plus roxithromycin
for non-severe community-acquired
pneumonia in adults with risk factors
RCT 2A+
Querol-
Ribelles
et al. [373]
Levoﬂoxacin vs. ceftriaxone plus
clarithromycin in the treatment of adults
with community-acquired pneumonia
requiring hospitalization
PCS 3C)
Salkind
et al. [374]
Fluoroquinolone treatment of community-
acquired pneumonia: a meta-analysis
MA 1A+
File et al. [403] Double-blind, randomized study of the
efﬁcacy and safety of oral
pharmacokinetically enhanced
amoxicillin-clavulanate (2000/125 mg)
vs. those of amoxicillin-clavulanate
(875/125 mg), both given twice daily
for 7 days, in the treatment of bacterial
community-acquired pneumonia in adults
RCT 2A+
File et al. [187] Efﬁcacy of a new pharmacokinetically
enhanced formulation of amoxicillin/
clavulanate (2000/125 mg) in adults with
community-acquired pneumonia caused
by Streptococcus pneumoniae, including
penicillin-resistant strains
MA 1B+
Garcia
et al. [392]
Lower mortality among patients with
community-acquired pneumonia
treated with a macrolide plus a
beta-lactam agent vs. a beta-lactam
agent alone
RCS 4C)
Petitpretz
et al. [368]
The efﬁcacy and safety of oral
pharmacokinetically enhanced
amoxycillin-clavulanate 2000/125 mg,
twice daily, vs. oral amoxycillin-clavulanate
1000/125 mg, three times daily, for the
treatment of bacterial community-acquired
pneumonia in adults
RCT 2A+
Siquier
et al. [369]
Efﬁcacy and safety of twice-daily
pharmacokinetically enhanced
amoxicillin/clavulanate (2000/125 mg) in
the treatment of adults with community-
acquired pneumonia in a country with
a high prevalence of penicillin-resistant
Streptococcus pneumoniae
RCT 2A+
Bergallo
et al. [381]
Safety and efﬁcacy of intravenous tigecycline
in the treatment of community-acquired
pneumonia: results from a double-blind
randomized phase 3 comparison study with
levoﬂoxacin
RCT 2A+
Ortiz-Ruiz
et al. [382]
Ertapenem vs. ceftriaxone for the treatment
of community-acquired pneumonia in adults:
combined analysis of two multicentre
randomized, double-blind studies
RCT 2A+
Yakovlev
et al. [384]
Ertapenem vs. cefepime for initial empirical
treatment of pneumonia acquired in
skilled-care facilities or in hospitals
outside the intensive care unit
RCT 2A+
Martinez [393] Monotherapy vs. dual therapy for
community-acquired pneumonia in
hospitalized patients
Expert opinion 4A+
Torres
et al. [400]
Moxiﬂoxacin monotherapy is effective in
hospitalized patients with community-
acquired pneumonia: the MOTIV study—a
randomized clinical trial
RCT 2A+
Von Baum
et al. [388]
Community-acquired pneumonia through
Enterobacteriaceae and Pseudomonas
aeruginosa: diagnosis, incidence and
predictors
RCS 4A+
Vetter
et al. [383]
A prospective, randomized, double-blind
multicentre comparison of
parenteral ertapenem and
ceftriaxone for the
treatment of hospitalized
adults with community-acquired
pneumonia
RCT 2A+
Torres
et al. [378]
Effectiveness of oral moxiﬂoxacin in
standard ﬁrst-line therapy in community-
acquired pneumonia
RCT 2A+
Dartois
et al. [370]
Tigecycline vs. levoﬂoxacin for the
treatment of community-acquired
pneumonia: European experience
RCT 2A+
File [367] Gemiﬂoxacin once daily for 5 days vs.
7 days for the treatment of community-
acquired pneumonia: a randomized,
multicentre, double-blind study
RCT 2A+
Lin et al. [371] An open-label, randomized comparison of
levoﬂoxacin and amoxicillin/clavulanate
plus clarithromycin for the treatment of
hospitalized patients with community-
acquired pneumonia
PCS 3B+
Lodise
et al. [363]
Comparison of beta-lactam and macrolide
combination therapy vs. ﬂuoroquinolone
monotherapy in hospitalized Veterans
Affairs patients with community-acquired
pneumonia
PCS 3A+
Murcia
et al. [386]
Clinical response to ertapenem in severe
community-acquired pneumonia: a
retrospective series in an elderly
population
RCS 4C)
Paladino
et al. [387]
Once-daily cefepime vs. ceftriaxone
for nursing home-acquired pneumonia
PCS 3A+
Schein
et al. [375]
A comparison of levoﬂoxacin and
moxiﬂoxacin use in hospitalized
community-acquired pneumonia (CAP)
patients in the US: focus on
length of stay
RCT 3A+
Tanaseanu
et al. [376]
Integrated results of two phase 3 studies
comparing tigecycline and levoﬂoxacin in
community-acquired pneumonia
PCS 3A+
Tanaseanu
et al. [377]
Efﬁcacy and safety of tigecycline vs.
levoﬂoxacin for community-acquired
pneumonia
PCS 3A+
Lui et al. [390] Role of ‘atypical pathogens’ among
adult hospitalized patients with
community-acquired pneumonia
PCS 3A+
Metersky
et al. [364]
Antibiotics for bacteraemic pneumonia:
improved outcomes with macrolides but
not ﬂuoroquinolones
RCS 4A+
Paul et al. [366] The need for macrolides in hospitalized
community-acquired pneumonia:
propensity analysis
PCS 3A+
Vardakas
et al. [379]
Respiratory ﬂuoroquinolones for the
treatment of community-acquired
pneumonia: a meta-analysis of randomized
controlled trials
SMA 1A+
Iannini
et al. [361]
A case series of macrolide treatment
failures in community-acquired
pneumonia
RCS 4A+
Rodriguez
et al. [399]
Combination antibiotic therapy improves
survival in patients with community-
acquired pneumonia and shock
PCS 3A+
Tessmer
et al. [365]
Impact of intravenous b-lactam/macrolide
vs. b-lactam monotherapy on mortality in
hospitalized patients with community-
acquired pneumonia
RCS 4C)
Kothe
et al. [385]
Outcome of community-acquired
pneumonia: inﬂuence of age, residence
status and antimicrobial treatment
PCS 3B+
Katz
et al. [397]
Safety and efﬁcacy of sequential i.v. to p.o.
moxiﬂoxacin vs. conventional combination
therapies for the treatment of
community-acquired pneumonia in
patients requiring initial i.v. therapy
PCS 3A+
Lode
et al. [398]
Sequential i.v./p.o. moxiﬂoxacin treatment
of patients with severe
community-acquired pneumonia
RCT 2A+
Martinez
et al. [404]
Addition of a macrolide to a beta-
lactam-based empirical antibiotic regimen
is associated with lower in-hospital
mortality for patients with bacteraemic
pneumococcal pneumonia
RCS 4C)
Romanelli
et al. [402]
Carbapenems in the treatment of
severe community-acquired pneumonia
in hospitalized elderly patients: a
comparative study against standard
therapy
PCS 3A+
Rzeszutek
et al. [362]
A review of clinical failures associated
with macrolide-resistant Streptococcus
pneumoniae
MA 1A+
Shefet
et al. [391]
Empirical antibiotic coverage of atypical
pathogens for community-acquired
pneumonia in hospitalized adults
MA 1A+
Wasserfallen
et al. [401]
Cost-effectiveness of full-course oral
levoﬂoxacin in severe community-
acquired pneumonia
RCT 2A+
Weiss and
Tillotson [405]
The controversy of combination vs.
monotherapy in the treatment of
hospitalized community-acquired
pneumonia
MA 1A+
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What is the recommended treatment for speciﬁc identiﬁed patho-
gens? Treatment for speciﬁc identiﬁed pathogens: Recommen-
dation:
Pathogen Recommended treatment
Highly resistant
S. pneumoniae (>8 mg/dL)
Levoﬂoxacin
Moxiﬂoxacin
Vancomycin, teicoplanin
Linezolid
MSSA Flucloxacillin
Cephalosporin II
Clindamycin
Levoﬂoxacin
Moxiﬂoxacin
MRSA Vancomycin, teicoplanin, ± rifampin
Linezolid
(Clindamycin if sensitive)
Ampicillin-resistant
H. inﬂuenzae
Aminopenicillin plus b-lactamase inhibitor
Levoﬂoxacin
Moxiﬂoxacin
Mycoplasma pneumoniae Doxycycline
Macrolide
Levoﬂoxacin
Moxiﬂoxacin
Chlamydophila pneumoniae Doxycycline
Macrolide
Levoﬂoxacin
Moxiﬂoxacin
Legionella spp. Levoﬂoxacin
Moxiﬂoxacin (most data availabe for levoﬂoxacin)
Macrolide (azithromycin preferred)
± rifampicin
Coxiella burnetii Doxycycline
Levoﬂoxacin
Moxiﬂoxacin
Acinetobacter baumanii Third-generation cephalosporin + aminoglycoside
Ampicillin-sulbactam
No experience in pneumonia for tigecycline.
There is still no convincing evidence that discordant treat-
ment of penicillin-resistant pneumococci negatively affects
clinical outcome [186,406–409]. Thus, pencillin may still be
used as a targeted treatment in pneumococci resistant up to
MIC 4 mg/L.
Recent publications have conﬁrmed that respiratory qui-
nolones, particularly levoﬂoxacin, offer advantages over mac-
rolide treatment for Legionella infection. If a macrolide is
used, azithromycin is the preferred drug. The superiority of
levoﬂoxacin and azithromycin is most relevant in patients
with severe Legionellosis [410–412].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Aspa
et al. [406]
Drug-resistant pneumococcal pneumonia:
clinical relevance and related factors
PCS 3A+
Bonnard
et al. [407]
Community-acquired bacteraemic
pneumococcal pneumonia in adults:
effect of diminished penicillin susceptibility
on clinical outcome
PCS 3B?
Falco
et al. [408]
Inﬂuence of penicillin resistance on outcome
in adult patients with invasive
pneumococcal pneumonia: is penicillin
useful against intermediately
resistant strains?
PCS 3A+
Lujan
et al. [409]
Prospective observational study of
bacteraemic pneumococcal pneumonia:
effect of discordant therapy on mortality
PCS 3B?
Plouffe
et al. [410]
Azithromycin in the treatment of
Legionella pneumonia requiring
hospitalization
PCS 3A+
Sabria
et al. [411]
Fluoroquinolones vs. macrolides in the
treatment of Legionnaires disease
PCS 3A+
Yu et al. [412] Levoﬂoxacin efﬁcacy in the treatment
of community-acquired legionellosis
MA 1A+
Peterson
et al. [186]
Penicillins for treatment of pneumococcal
pneumonia: does in vitro resistance
really matter?
MA 1A+
What should be the duration of treatment?
Recommendation: The duration of treatment should
generally not exceed 8 days in a responding patient [C2].
Biomarkers, particularly PCT, may guide shorter treatment
duration.
The focus of recent studies dealing with treatment dura-
tion has been the assessment of post-discharge outcomes.
European authors report a declining duration of hospitaliza-
tion (and therefore i.v. treatment) [413]. Co-morbidity, par-
ticularly cardiopulmonary and neurological conditions, has
been associated with rehospitalizations but not treatment
failures due to inadequately short (i.v.) treatment duration
[414]. On the other hand, ongoing clinical inﬂammation
despite clinical recovery has been described [415]. However,
it is improbable that the level of inﬂammation can be inﬂu-
enced by prolonged treatment duration.
Most patients with hospitalized non-severe pneumonia are
appropriately treated with 7 days of antibiotics. Although
there is only one study addressing treatment duration in
nosocomial pneumonia, it appears reasonable to believe that
treatment duration for severe pneumonia should not be dif-
ferent from nosocomial pneumonia. According to this study,
8 days appears to be comparable to 15 days of treatment.
However, in the presence of P. aeruginosa and other non-fer-
menters, clinicians must be aware of an increased risk of
relapses [416].
Recently, biomarkers have been described as useful tools
to safely reduce antibiotic treatment duration. Biomarkers
can guide treatment duration by the application of prede-
ﬁned stopping rules for antibiotics [417–419]. It has been
shown that such rules work even in most severe cases,
including pneumonia with septic shock, and even if clinicians
are allowed to overrule the predeﬁned stopping rule
[420,421].
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Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Bouadma
et al. [420]
Use of procalcitonin to reduce patients’
exposure to antibiotics in intensive care
units (PRORATA trial): a multicentre
randomized controlled trial
RCT 2A+
Capelastegui
et al. [413]
Declining length of hospital stay for
pneumonia and post-discharge outcomes
PCS 3B)
Chastre
et al. [416]
Comparison of 8 vs. 15 days of antibiotic
therapy for ventilator-associated
pneumonia in adults: a randomized trial.
JAMA 2003; 290(19):2588–2598.
Ref ID: 4116
RCT 2A+
Christ-Crain
et al. [417]
Procalcitonin guidance of antibiotic therapy
in community-acquired pneumonia: a
randomized trial
RCT 2B+
El Moussaoui
et al. [422]
Comparison of 3 days with 8 days of
intravenous amoxicillin
RCT 2A+
Jasti et al. [414] Causes and risk factors for rehospitalization
of patients hospitalized with
community-acquired pneumonia
PCS 3A+
Kristoffersen
et al. [418]
Antibiotic treatment interruption of
suspected lower respiratory tract
infections based on a single procalcitonin
measurement at hospital admission—a
randomized trial
RCT 2A+
Nobre
et al. [421]
Use of procalcitonin to shorten antibiotic
treatment duration in septic patients: a
randomized trial
RCT 2A+
Schuetz
et al. [419]
Effect of procalcitonin-based guidelines vs.
standard guidelines on antibiotic use in
lower respiratory tract infections: the
ProHOSP randomized controlled trial
RCT 2A+
Yende
et al. [415]
Inﬂammatory markers at hospital discharge
predict subsequent mortality after
pneumonia and sepsis
PCS 3A+
When should i.v. treatment be used and when should the switch
to oral occur?
Recommendation: In ambulatory pneumonia, treatment
can be applied orally from the beginning [A3]. Some carefully
selected hospital inpatients may also be candidates for exclu-
sively oral treatment.
In hospitalized patients, sequential treatment should be
considered in all patients except the most severely ill. The
optimal time to switch to oral treatment is also unknown;
this decision should be guided by the resolution of the most
prominent clinical features at admission [A3]. In most
patients it is probably not necessary to observe patients in
hospital after having switched to oral treatment [A3]. Switch
to oral treatment after reaching clinical stability is also safe
in patients with severe pneumonia [A2].
The efﬁcacy and safety of early switch therapy has been
conﬁrmed by several studies and meta-analyses [423,424].
Hospitalized patients with non-severe pneumonia, no sepsis
and no reason for impaired intestinal absorption are candi-
dates for oral treatment from the beginning [425]. Switch
therapy is safe and may be guided by an algorithm [426] or
pathway [427]. The routine practice of in-hospital observation
after the switch from i.v. to oral antibiotics for patients with
CAP may be avoided [428]. Also in patients with severe pneu-
monia, switch to oral antimicrobial treatment after 3 days of
intravenous treatment and treatment response is safe [429].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Athanassa
et al. [423]
Early switch to oral treatment in patients
with moderate to severe community-
acquired pneumonia: a meta-analysis
MA 1A+
Lee and
Lindstrom
[424]
Early switch to oral antibiotics and early
discharge guidelines in the management
of community-acquired pneumonia
PCS 3B+
Marras
et al. [425]
Efﬁcacy of exclusively oral antibiotic therapy
in patients hospitalized with non-severe
community-acquired pneumonia: a
retrospective study and meta-analysis
RCS + MA 4B + 1B+
Nathan
et al. [428]
In-hospital observation after antibiotic
switch in pneumonia: a national evaluation.
Am J Med 2006; 119: 512–517. Ref ID: 603
PCS 3A+
Oosterheert
et al. [429]
Effectiveness of early switch from
intravenous to oral antibiotics in
severe community-acquired pneumonia:
multicentre randomized trial. BMJ
2006; 333: 1193–1196. Ref ID: 32
RCT 2A+
Shindo
et al. [427]
Implication of clinical pathway care for
community-acquired pneumonia in a
community hospital: early switch from
an intravenous beta-lactam plus a
macrolide to an oral respiratory
ﬂuoroquinolone
RCS 4A+
van der
Eerden
et al. [426]
Evaluation of an algorithm for switching
from i.v. to p.o. therapy in clinical practice
in patients with community-acquired
pneumonia
PCS 3A+
Which additional therapies are recommended?
Recommendation: All patients should be subject to early
mobilization [A3].
Low molecular heparin should be given in patients with
acute respiratory failure [A3]. The use of non-invasive venti-
lation is not yet standard care but can be considered, partic-
ularly in patients with COPD [B3] and ARDS [A3].
The treatment of severe sepsis and septic shock is con-
ﬁned to supportive measures [A3].
Steroids are not recommended in the treatment of pneu-
monia [A3].
Early mobilization has been shown to be associated with
better outcome. For the purpose of the study, early mobili-
zation was deﬁned as movement out of bed with change
from horizontal to upright position for at least 20 min during
the ﬁrst 24 h of hospitalization, with progressive movement
each subsequent day during hospitalization [430].
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Several studies indicate that non-invasive ventilation (NIV)
may also work in patients with pneumonia, particularly in
patients with COPD [431,432]. Non-invasive ventilation has
been shown to reduce intubation in patients with ARDS in
54% of treated cases [433]. It may be feasible and also
effective in do-not-intubate patients [434] and, therefore,
may be an option even in palliative care.
Despite one promising controlled trial [435], two meta-
analyses show that at present steroids cannot be recom-
mended in the treatment of patients with CAP [436,437].
One meta-analysis failed to ﬁnd an effect for the following
interventions: activated protein C, non-invasive mechanical
ventilation, anticoagulants, immunoglobulin, granulocyte-col-
ony-stimulating factor, statins, probiotics, chest physiother-
apy, antiplatelet drugs, over-the-counter cough medications,
beta(2)-agonists, inhaled nitric oxide and angiotensin-convert-
ing enzyme inhibitors [438].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Antonelli
et al. [433]
A multiple-centre survey on the use in
clinical practice of non-invasive
ventilation as a ﬁrst-line intervention
for acute respiratory distress syndrome
PCS 3A+
Bulow and
Thorsager [434]
Non-invasive ventilation in do-not-intubate
patients: 5-year follow-up on a 2-year
prospective, consecutive cohort study
RCS 4B+
Confalonieri
et al. [435]
Hydrocortisone infusion for severe
community-acquired pneumonia: a
preliminary randomized study
RCT 2C)
Confalonieri
et al. [431]
Acute respiratory failure in patients
with severe community-acquired
pneumonia. A prospective randomized
evaluation of non-invasive ventilation
RCT 2B+
Ferrer
et al. [432]
Non-invasive ventilation in severe
hypoxaemic respiratory failure: a
randomized clinical trial
RCT 2B+
Gorman
et al. [436]
Corticosteroid treatment of severe
community-acquired pneumonia.
MA 1A+
Mundy
et al. [430]
Early mobilization of patients hospitalized
with community-acquired pneumonia.
Chest 2003; 124(3):883–889. Ref ID: 4438
PCS 3A+
Salluh
et al. [437]
The role of corticosteroids in severe
community-acquired pneumonia: a
systematic review
MA 1A+
Siempos
et al. [438]
Adjunctive therapies for community-
acquired pneumonia: a systematic review
MA 1A+
When should aspiration pneumonia be suspected?
Recommendation: There is no agreed deﬁnition. Aspira-
tion pneumonia should be suspected in those with CAP
which either:
1 follows an episode of witnessed aspiration; or
2 occurs in the presence of risk factors for aspiration,
including reduced consciousness level and dysphagia due
to mechanical or neurological upper digestive tract dys-
function [C3].
Evidence Table
MA, meta-analysis (or systematic review), RCT, random-
ized controlled trial, PCS, prospective cohort study, RCS,
retrospective cohort study, CCS, case-control study, CSS,
cross-sectional study, SR, systematic review
Table of evidences
Reference Objective Design Evidence
Adams
et al. [439]
To assess role of lipid laden macrophages
in diagnosis
PCS 3B+
Chen
et al. [440]
Study of pneumonia in patients with
dementia
RCS 2B+
DeToledo
et al. [441]
To assess AP frequency after epileptic ﬁts RCS 4A+
El Solh
et al. [6]
BAL study of microbiology of nursing home
patients
PCS 4A+
Kadowaki
et al. [442]
Antibiotic trial RCT 2B+
Leroy
et al. [44]
Study of ICU admissions RCS 4B+
Mier
et al. [443]
PSB study of ICU admissions PCS 3B+
Mylotte
et al. [444]
To compare features of aspiration
pneumonia (AP) with aspiration
pneumonitis
RCS 4A+
Reza
et al. [445]
To compare features of AP in patients from
long-term care facilities and the community
RCS 4A+
Teramoto
et al. [446]
To identify frequency of aspiration
pneumonia in hospitalized
adults with CAP
PCS 3B?
What empirical antibiotic treatment is recommended for aspira-
tion pneumonia?
Recommendation:
Hospital ward, admitted
from home
ICU or admitted from
nursing home
Oral or i.v.
b-lactam/b-lactamase inhibitor
or
Clindamycin
or
i.v. cephalosporin + oral
metronidazole
or
moxiﬂoxacin
Clindamycin + cephalosporin
or
Cephalosporin + metronidazole
Studies (mainly of clindamycin vs. a comparator antibiotic)
have mainly included only small numbers of patients (<40 per
treatment arm) and do not reach consistent conclusions
regarding the superiority of one antibiotic regime over another
[442,447–451]. In one larger open RCT, clinical response was
identical in those treated with moxiﬂoxacin and those treated
with ampicillin–sulbactam, but a signiﬁcant difference could
have been missed due to lack of blinding and because target
recruitment was not achieved [452]. Our recommendation is
based on knowledge of likely causative pathogens [6,44,443]
and the antibiotic regimes used in these studies.
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Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Table of evidences
Reference Objective Design Evidence
Allewelt
et al. [447]
Ampicillin/sulbactam vs. clindamycin +
cephalosporin
RCT 2B)
Bartlett and
Gorbach [448]
Penicillin G vs. clindamycin in anaerobic
infection
RCT 3B+
El Solh et al. [6] BAL study of microbiology of NH
patients
PCS 4A+
Fernandez Sabe
et al. [449]
Co-amoxiclav in anerobic infection PCS 3B+
Gudiol et al. [450] Clindamycin vs. penicillin RCT 2B+
Kadowaki
et al. [442]
Ampiciilin/sulbactam vs. clindamycin
vs. panipenem/betamiprom
RCT 2B)
Leroy et al. [44] Study of ICU admissions PCS 4B+
Mier et al. [443] PSB study of ICU admissions PCS 3B+
Ott et al. [452] Comparison of moxiﬂoxacin vs.
ampicillin/sulbactam
RCT 2C)
Perlino [451] Clindamycin vs. metronidazole RCT 3B)
How should response be assessed and should chest radiograph be
repeated?
Recommendation: Response to treatment should be mon-
itored by simple clinical criteria, including body temperature,
respiratory and haemodynamic parameters. The same param-
eters should be applied to judge suitability for hospital dis-
charge [A3]. Complete response, including radiographic
resolution, requires longer time periods. C-reactive protein
should be measured on days 1 and 3/4, especially in those
with unfavourable clinical parameters. The same clinical
parameters should be applied to judge suitability for hospital
discharge [A3]. Discharge decisions should be based on
robust markers of clinical stabilization [A3].
Repeated daily measurement of the PSI found a rising PSI
to be related to mortality in one study, but is not practical
in routine practice [453].
A number of studies have used C-reactive protein levels
on admission [454] and repeated measurements after admis-
sion, both for all admissions [262,285,454,455] and those
admitted to the ICU [456], to predict clinical outcome.
Measurement of CRP on day 3 [285,454] or day 4 [262,455]
appears to be most useful. Failure of CRP to fall by 50% by
day 4 was associated with ﬁvefold increase in mortality,
ventilation and complications [455].
Procalcitonin may also be useful but has not been sufﬁ-
ciently studied to make a recommendation [454].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Bruns
et al. [285]
To study relation between day 3 and 7
CRP levels and inappropriate
antibiotic therapy
PCS 3C+
Chalmers
et al. [455]
To study CRP as severity predictor in CAP PCS 3A+
Chen
et al. [453]
To assess value of repeated PSI
measurement as mortality predictor
PCS 3A+
Coelho
et al. [456]
To study relationship between CRP and
clinical course of CAP on the ICU
PCS 3A+
Hohenthal
et al. [262]
To study relationship between daily
CRP and complications in CAP
PCS 3A+
Menendez
et al. [454]
Study of relationship between cytokines
and treatment failure
PCS 3A+
How should the non-responding patient be assessed?
Recommendation: Two types of treatment failures, non-
responding pneumonia and slowly resolving pneumonia,
should be differentiated [A3]. Non-responding pneumonia
occurring in the ﬁrst 72 h of admission is usually due to anti-
microbial resistance or an unusually virulent organism or a
host defence defect. Non-response after 72 h is usually due
to a complication. The evaluation of non-responding pneu-
monia depends on the clinical condition. There are no trials
of different approaches to the non-responding patient to
guide this recommendation. In unstable patients, full reinves-
tigation followed by a second empirical antimicrobial treat-
ment regimen should be carried out. The latter may be
withheld in stable patients. Slowly resolving pneumonia
should be reinvestigated according to clinical needs, the con-
dition of the patient and his/her individual risk factors [C3].
Exacerbations of chronic obstructive pulmonary disease
Which hospitalized patients with COPD exacerbations should
receive antibiotics?
Recommendation:
1 Patients with all three of the following symptoms:
increased dyspnoea, sputum volume and sputum puru-
lence (a type I Anthonisen exacerbation) [A2].
2 Patients with only two of the above three symptoms (a
type II Anthonisen exacerbation) when increased puru-
lence of sputum is one of the two cardinal symptoms
[A2].
3 Patients with a severe exacerbation that requires invasive
or non-invasive mechanical ventilation [A2].
4 Antibiotics are generally not recommended in Anthonis-
en type II without purulence and type III patients (one or
less of the above symptoms) [A2].
New information. Recommendation not changed.
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Fever is not observed in 30% of exacerbations [457]. The
relationship between purulence and bacterial growth is
conﬁrmed in one study [458]. In addition, a bronchoscopic
study found that referred purulence by the patient had a
sensitivity of 89.5%, a speciﬁcity of 76%, a predictive positive
value of 77% and a negative predictive value of 89% to detect
bacteria in protected specimen brush bronchoscopic samples
in COPD hospitalized patients with exacerbation [459].
However, small studies found a weak association between
sputum purulence and bacterial load [460] or bacterial
growth [461]. In this later study Gram stain of sputum was
the best indicator of bacterial infection. Randomized-con-
trolled trials are needed to clarify which COPD exacerbated
patients requiring hospitalization would beneﬁt from antibiot-
ics. Biomarkers such as procalcitonin may help to detect
those exacerbations requiring antibiotics but the information
available comes from a single-centre randomized study [462].
In one case–control study of AECOPD, viruses were
found in an important percentage of AECOPD patients
requiring hospitalization [168]. In one study focusing on
Mycoplasma pneumoniae, this microorganism was involved in
32% of hospitalizations [463].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Allegra
et al. [458]
To study the relationship between
objective purulence and the presence
of bacteria
PCS 3B+
Lieberman
et al. [457]
To study the frequency of fever in
exacerbations
PCS 3C+
Rohde
et al. [168]
A case control study to investigate the role
of different viruses on acute exacerbations
of chronic obstructive pulmonary disease
(AECOPD)
CCS 3C+
Lieberman
et al. [463]
To study the role of Mycoplasma pneumoniae
in hospitalized patients with AECOPD
PCS 2C+
Soler
et al. [459]
To study the association between purulence
and bacterial bronchoscopic samples
PCS 3A+
Brusse-Keizer
et al. [460]
To study the association between sputum
colour and sputum bacterial load
PCS 3C)
Burley
et al. [461]
To study the association between symptoms
and Gram stain and sputum bacterial
growth
PCS 3B+
Stolz
et al. [462]
To study the value of procalcitonin
to decrease the use of antibiotics in
exacerbated COPD
RCT 2A+
What stratiﬁcation of patients with COPD exacerbation is recom-
mended in order to direct treatment?
Recommendation:
Group A: admitted to hospital without risk factors for P. aeru-
ginosa infection [A3].
Group B: admitted to hospital with risk factors for P. aerugin-
osa [A3].
New information. Recommendation reworded, but not chan-
ged.
It is conﬁrmed that P. aeruginosa is associated with a small
percentage of exacerbations that need hospitalization
[157,160]. P. aeruginosa exacerbations seem to be indepen-
dent of the bronchial bacterial load [169]. P. aeruginosa
represented the 17% of isolated microorganisms in 328 out
of 494 episodes in Taiwan. The isolation of P. aeruginosa was
associated with poorer outcome [464]. In a case-control
study the isolation of multidrug-resistant microorganisms in
AECOPD, including P. aeruginosa, was associated with higher
mortality [465].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Groenewegen
and Wouters
[157]
To study bacterial infections in COPD
exacerbated patients that need
hospitalization
PCS 3C+
Ko et al. [160] To study sputum microbiology in
AECOPD
PCS 4C+
Rosell et al. [169] To study the microbiological
determinants of AECOPD
MA 1A+
Lin et al. [464] To study the microbiology of
AECOPD
PCS 3B+
Montero
et al. [465]
To study the association between
multi-resistant P. aeruginosa and
outcome of AECOPD
CCS 4b+
What are the risk factors for P. aeruginosa?
Recommendation:
P. aeruginosa should be considered in the presence of at
least two of the following.
1 Recent hospitalization [A3].
2 Frequent (>4 courses per year) or recent administration
of antibiotics (last 3 months) [A3].
3 Severe disease (FEV1 < 30%) [A3].
4 Oral steroid use (>10 mg of prednisolone daily in the
last 2 weeks) [A3].
One study has investigated [84] the risk factors for P. aerugin-
osa. Prior use of antibiotics was a risk factor for P. aeruginosa
infection (OR 6.06). Inﬂuenza vaccination was a protective
factor (OR 0.15). We do not know the negative predictive
value of this ﬁnding. A study of 193 patients with acute exac-
erbation identiﬁed the following variables as independent
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predictors of Gram-negative bacilli and P. aeruginosa infec-
tion: FEV1 < 35% of predicted value, systemic steroid use
and prior antibiotic therapy within the preceding 3 months.
The negative predictive value of this rule was 89% [466]. A
recent study from Garcia Vidal et al. [467] found that the
risk factors for P. aeruginosa in the initial sputum were the
BODE index, admissions in the previous year, systemic ste-
roid treatment and previous isolation of P. aeruginosa.
However, in a very large retrospective study P. aeruginosa
was found independently of the severity (uncomplicated AE-
COPD vs. complicated AECOPD; 6% vs. 9.4%) [468].
Despite the fact that recommendations for treating Pseudo-
monas aeruginosa remain unchanged in these guidelines, some
members of the panel disagreed about covering Pseudomonas
aeruginosa as initial empirical treatment in patients at risk.
The rationale behind this disagreement lies in the studies that
consider that P. aeruginosa is a colonizer and not a pathogen.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Monso´
et al. [84]
To study the risk factors for bacterial
exacerbations
PCS 3C+
Lode et al. [466] To study the risk factors for bacterial
aetiology in AECOPD
PCS 3B+
Garcia-Vidal
et al. [467]
To study the risk factors for P.
aeruginosa isolation in AECOPD
PCS 3B+
Kahn et al. [468] To study the entry microbiological
criteria in antibiotic trials of AECOPD
RCT 4B+
Which microbiological investigations are recommended for the
hospitalized patient with COPD exacerbation?
Recommendation: Sputum cultures or endotracheal aspi-
rates (in mechanically ventilated patients) should be obtained
and are a good alternative to bronchoscopic procedures for
evaluation of the bacterial burden by potential pathogenic
microorganisms [A3].
Recommendation modiﬁed.
Is there new information about pathogens associated with
COPD? Most bacterial isolates from patients with COPD are
Streptococcus pneumoniae and Haemophilus inﬂuenzae, but Mor-
axella catarrhalis has recently been shown to be associated
with approximately 10% of all exacerbations of COPD [166].
In the case of H. inﬂuenzae, it is now clear that patients can
be colonized by an identical strain of H. inﬂuenzae over
extended periods of time despite intermittent cultures being
negative for the colonizing (or any other) H. inﬂuenzae strain
[469]. Over the course of the lifetime of a COPD patient,
the ﬂora associated with exacerbations does change. In
severe cases with FEV1 < 50% of normal, Gram-negative
ﬂora, including P. aeruginosa, become increasingly important
as associated pathogens [458]. Acquisition of a new strain of
P. aeruginosa is associated with exacerbations [85,458].
Is there a causal relationship between infections and exacerba-
tions of COPD? Purulent sputum is almost always associated
with signiﬁcantly positive cultures [458]. A causal relationship
between infections and exacerbations of COPD has not been
established but the association between the two is very
strong. In a prospective analysis of COPD patients with exac-
erbations requiring hospitalization, Papi et al. [167] showed
that the frequency of isolation from sputum of bacteria and
viruses was much higher during exacerbations than during sta-
ble periods, and that eosinophilia within sputum was higher in
viral infections. Furthermore, in a longitudinal study of bacte-
rial load in sputum amongst patients with COPD, the FEV1
decline was mirrored by an increase in sputum bacterial load
[470]. A recent detailed longitudinal study found that quantita-
tive counts of established sputum ﬂora do not greatly change
between stable and exacerbation periods in COPD patients
[471]. Sethi et al. [472] have demonstrated that during exacer-
bations of COPD caused by H. inﬂuenzae there is a speciﬁc
immune response to the infecting strain of H. inﬂuenzae.
Does PSI sampling increase the diagnostic yield over other
respiratory tract samples? In patients with cystic ﬁbrosis, PSI
sampling does not increase the culturable yield of P. aerugin-
osa over regular sputum sampling [473].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Aaron
et al. [473]
To determine if PSI of bioﬁlms of
cystic ﬁbrosis patients yields additional
P. aeruginosa isolates cf sputum culture
PCS 3A? small
numbers
Allegra
et al. [458]
Colorimetric and detailed
microbiological assessment of sputum
in a large sample of COPD patients
of varying clinical severity
PCS 3A+
Murphy
et al. [166]
To establish causal link viz AECOPD and
Moraxella in a longitudinal cohort
with molecular microbiological testing
of sputum and serology
PCS 3A? there
have been
previous
studies that
found little
evidence of
moraxella
involvement
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Murphy
et al. [469]
Longitudinal molecular analysis of H.
inﬂuenzae isolates from sputum
PCS 3A+
Papi
et al. [167]
Prospective study of diagnostic yield
from sputa from patients during and
after exacerbations of COPD
PCS 3A+
Sethi
et al. [472]
Longitudinal study of COPD patients
including detailed analysis of serological
responses during exacerbations
PCS 3A+
Wilkinson
et al. [470]
Correlation of sputum bacterial load
with clinical features and severity of
longitudinal series of COPD patients
PCS 3A+
Sethi
et al. [471]
Detailed longitudinal study of quantitative
sputum counts comparing stable and
exacerbation periods
PCS 3A+
Murphy
et al. [85]
Acquisition of a new stain of P. aeruginosa is
associated with exacerbations of COPD
PCS 3A+
Which initial antimicrobial treatments are recommended for
patients admitted to hospital with COPD exacerbation?
Recommendation:
1 In patients without risk factors for P. aeruginosa several
options for antibiotic treatment are available. The selec-
tion of one or other antibiotic should depend on the
severity of the exacerbation, local pattern of resistance,
tolerability, cost and potential compliance. Amoxicillan-
clavulanic acid is recommended, while levoﬂoxacin and
moxiﬂoxacin are alternatives [A2].
2 In patients with risk factors for P. aeruginosa, ciproﬂoxacin
(or levoﬂoxacin 750 mg/24 h or 500 mg twice daily) is the
antibiotic of choice when the oral route is available. When
parenteral treatment is needed ciproﬂoxacin, or a b-lac-
tam with antipseudomonal activity, are the options avail-
able. The addition of aminoglycosides is optional [A2].
3 The use of the oral or intravenous route should be
guided by the stability of the clinical condition and the
severity of exacerbation. Switch (intravenous to oral)
should be done by day 3 of admission if the patient is
clinically stable [A3].
Oral gemiﬂoxacin and levoﬂoxacin (750 mg/24 h) over
5 days may be used to effectively treat AECOPD patients
that require hospitalization [474,475]. This information
comes from two randomized clinical trials that compare these
two quinolones with standard treatments (10 days) in hospi-
talized and non-hospitalized patients with AECB.
A meta-analysis of randomized controlled-trials (including
six studies on hospitalized AECOPD patients), comparing
what they called ﬁrst-line (amoxicillin, ampicillin, trimetro-
prim-sulphamethoxazol) with second-line antibiotics (amoxi-
cillin-clavulanic acid, macrolides, second- or third-generation
cephalosporins) for AECOPD, showed that ﬁrst-line antibiot-
ics were associated with lower treatment success compared
with second-line antibiotics (mainly macrolides and amoxicil-
lin-clavulanate; OR., 0.51) [476]
Preferred Alternative
Without risk factors for P. aeruginosa Co-amoxiclav Levoﬂoxacin
Moxiﬂoxacin
+ Risk factors for P. aeruginosa Ciproﬂoxacina Piperacillin/
tazobactam i.v.
aLevoﬂoxacin 750 mg/24 h or 500 mg twice daily is an alternative.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Wilson
et al. [474]
A randomized open label study comparing
oral gemiﬂoxacin for 5 days with
ceftriaxone i.m./cefuroxime orally 10 days
in hospitalized patients with AECB
RCT 2A+
Martı´nez
et al. [475]
A randomized trial comparing 5 days of
levoﬂoxacin (750 mg/24 h) with
amoxicillin–clavulanic acid for 10 days
RCT 2C+
Dimopoulos
et al. [476]
A meta-analysis comparing ﬁrst-line
with second-line antibiotics in AECOPD
SR 1A+
How should the non-responding patient with COPD exacerbation
be assessed?
Recommendation:
1 After close re-evaluation of non-infectious causes of fail-
ure (i.e. inadequate medical treatment, embolisms,
cardiac failure, other) a careful microbiological reassess-
ment, as mentioned in the section on microbiological
diagnosis, should be considered [C3].
2 Change to an antibiotic with good coverage against P. aeru-
ginosa, S. pneumoniae resistant to antibiotics and non-fer-
menters, and subsequent adjustment of the new antibiotic
treatment according to microbiological results, should be
considered for treatment in cases of failure [C3].
New information. Recommendation not changed.
In one study colonization by non-fermenting GNB, mainly
Pseudomonas aeruginosa, was signiﬁcantly associated with
non-invasive mechanical ventilation failure in patients with
AECOPD admitted to the ICU [477].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
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Reference Objective Design Evidence
Ferrer
et al. [477]
To study microbiological determinants
associated with NIMV failure in AECOP
PCS 3A+
Exacerbations of bronchiectasis
General recommendations for exacerbations of bronchiectasis.
Recommendation:
1 Periodic surveillance of colonization should be consid-
ered [B3].
2 Antibiotic treatment should be given to patients with
exacerbations [B3].
3 Obtaining a sputum sample for culture before starting
antibiotic treatment should be carried out in most
cases and particularly in those requiring hospitalization
[B3].
4 For empirical antibiotic treatment patients should be
stratiﬁed according to the potential risk of Pseudomonas
spp infection [B3] (see section What are the risk factors
for P. aeruginosa? above).
5 Empirical antibiotics should be adjusted or modiﬁed
according to sputum culture results [A3].
New information. Recommendation not changed.
The combination of ciproﬂoxacin and inhaled tobramycin
may improve microbiological and clinical outcome. However,
in 50% of patients treated with inhaled tobramycin wheezing
was observed [478].
Prolonged antibiotic therapy has shown small beneﬁt in
modifying the outcome of purulent bronchiectasis [479] [B2].
What antibiotics are recommended for exacerbations of bronchi-
ectasis? [C4]. The risk of P. aeruginosa infection should be
considered. No validated risk factors are available; however,
risk appears to be related to recent antibiotic therapy or
hospitalization, serious disease or prior isolation of Pseudo-
monas species [89]
Recommendation:
Oral treatment Parenteral treatment
No risk of
Pseudomonas spp.
Amoxicillin-clavulanate
Moxiﬂoxacin
Levoﬂoxacin
Risk of
Pseudomonas spp.a
Ciproﬂoxacinb Ceftazidime, or
carbapenem, or
piperacillin-
tazobactam
aUse the same criteria mentioned for chronic obstructive pulmonary
disease exacerbation.
bLevoﬂoxacin 750 mg/24 h or 500 mg twice daily is an alternative.
Evidence Table
MA, meta-analysis (or systematic review); RCT,
randomized controlled trial; PCS, prospective cohort study;
RCS, retrospective cohort study; CCS, case-control study;
CSS, cross-sectional study; SR, systematic review
Reference Objective Design Evidence level
Evans
et al. [479]
To identify the role of prolonged antibiotic
therapy in modifying the outcome of
purulent bronchiectasis
MA 1B)
Bilton
et al. [478]
To study the effect of adding inhaled
tobramycin solution to oral ciproﬂoxacin
for the treatment of acute exacerbations of
non-CF bronchiectasis in patients with
P. aeruginosa infection
RCT 2A)
Angrill
et al. [89]
To investigate the incidence, diagnostic yield
of non-invasive and bronchoscopic
techniques, and risk factors for airway
colonization in patients with bronchiectasis
in a stable clinical situation
PCS 3B+
Prevention
Prevention by methods other than vaccination
Does oral immunization with bacterial extracts prevent LRTI?
Recommendation: In patients with chronic bronchitis
(CB) or COPD H. inﬂuenzae oral vaccine [B1] or bacterial
extracts (OM-85 BV) [B2] should not be given.
New information [480–483]. Recommendation not
changed.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study, CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Cogo
et al. [480]
Prophylaxis of AE of COPD by a
sublingual vaccine
CCS 3C+
Foxwell
et al. [481]
Cochrane: H. inﬂuenza oral
vaccine for the prevention of
AE of COPD
MA 1A+
Steurer-Stey
et al. [482]
BronchVaxom: meta-analysis MA 1B)
Tricarico
et al. [483]
Oral bacterial (mechanical lysis)
sublingual
RCT 2A+
What is the role of prophylactic antibiotic therapy in chronic bron-
chitis or COPD?
Recommendation: In patients with CB or COPD, oral or
parenteral antibiotics should not be given for prevention
[A1].
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New information [484,485]. The PULSE study investigated
whether a pulsed therapy with moxiﬂoxacin every 8 weeks
for 5 days over a 6-month period was able to prolong the
time to the next exacerbation in COPD patients in compari-
son to placebo. The study was negative, although there was
some trend that patients with purulent sputum showed a
prolongation of the time to the next acute exacerbation
[487].
Recommendation not changed.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Black
et al. [484]
Prophylatic antibiotics for chronic bronchitis MA 1A+
Smucny
et al. [485]
Antibiotics for acute bronchitis MA 1A)
Sethi
et al. [487]
Proof-of-concept study evaluates whether
intermittent pulsed moxiﬂoxacin treatment
(5 days/8 weeks) could reduce the
frequency of these exacerbations
RCT 2A)
What is the role of prophylactic antibiotic therapy in patients
with COPD or bronchiectasis? (a) COPD
Recommendation: The use of nebulized antibiotics or
intermittent long-term macrolide therapy is not recom-
mended in COPD patients in general [C4].
The use of nebulized antibiotics for the prevention of
LRTI has only been studied in small groups of patients with
COPD.
One randomized clinical trial has investigated the use of
erythromycin (2 · 250 mg/day) over 12 months in COPD
patients, with the aim of reducing moderate to severe exac-
erbations in these patients [486]. In total, 109 outpatients
have been included in the trial: 69 (63%) male; 52 (48%) cur-
rent smokers; mean (SD) age, 67.2 (8.6) years; FEV1, 1.32
(0.53) L; FEV1% predicted, 50 (18%). Thirty-eight (35%) of the
patients had three or more exacerbations in the year before
recruitment, with no differences between treatment groups.
There was a total of 206 moderate to severe exacerbations;
125 occurred in the placebo arm. Ten in the placebo group
and nine in the macrolide group withdrew. Generalized linear
modelling showed that the rate ratio for exacerbations for
the macrolide-treated patients compared with placebo-trea-
ted patients was 0.648 (95% conﬁdence interval, 0.489, 0.859;
p 0.003) and that these patients had shorter-duration exacer-
bations compared with those on placebo.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Seemungal
et al. [486]
To study the efﬁcacy of
adding 2 · 250 mg erythromycin
to the existing treatment regimen
in patients with COPD
RCT 2A+
(b) Bronchiectasis—nebulized antibiotics
Recommendation: There is not enough evidence to
recommend the use of nebulized antibiotics (tobramycin) in
non-CF-bronchiectasis [C2].
Nebulized tobramycin has been used with some success in
cystic ﬁbrosis patients. In non-CF-bronchiectasis patients,
only small studies have been done. One found no effect
[488] and one [489] found a decrease of hospital admission
and some clinical improvement. Clear evidence for a recom-
mendation to use inhaled tobramycin could not be drawn
from these studies.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review [C4].
Reference Objective Design Evidence
Drobnic et al. [488] To study aerosolised tobramycin vs. placebo
in non-CF bronchiectasis
RCT 2B)
Barker et al. [489] To study aerosolised tobramycin vs. placebo
in non-CF bronchiectasis
RCT 2B+
(c) Bronchiectasis—macrolides
Recommendation: There is not enough evidence to
recommend the use of intermittent long-term macrolide
therapy in non-CF-bronchiectasis in general [C2].
Use of intermittent macrolide therapy has been successful
in patients with CF and patients following lung transplanta-
tion. The number of studies investigating non-CF-bronchiec-
tasis patients is low. Besides some letters, case reports and
very small studies [490], one retrospective study has been
published. This study investigated prophylaxis with 3· azi-
thromycin/week in bronchiectasis patients. A reduction of
acute exacerbations of 50% has been observed, as well as an
increase of FEV1 [491].
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Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Cymbala
et al. [490]
To study the efﬁcacy of the addition
of 6-months’ twice-weekly azithromycin
to the existing treatment regimen
in patients with bronchiectasis
RCT 2A+
Anwar
et al. [491]
To study the effects of long-term
low-dose azithromycin in patients
with non-CF bronchiectasis
RCS 4C+
Does antibiotic treatment of upper respiratory tract infections pre-
vent LRTI?
Recommendation: Antibiotics should not be given as
treatment for URTI to prevent LRTI [A1].
No new information. Recommendation not changed.
Does treatment with inhaled steroids or long-acting beta-2-agon-
ists or long-acting anti-muscarinics prevent LRTI?
Recommendation: Inhaled steroids [B1] or long-acting
beta-2-agonists [C4] or long-acting anti-muscarinics [C4]
should not be used to prevent LRTI (this does not mean that
they might not prevent exacerbations of COPD, which is an
issue beyond the scope of this document).
No new information. Recommendation not changed.
Does regular physiotherapy prevent LRTI?
Recommendation: Physiotherapy should not be used as a
preventive measure against LRTI [C4].
No new information. Recommendation not changed.
Do antiviral substances prevent inﬂuenza virus infection?
Recommendation: Prevention of inﬂuenza by antiviral sub-
stances should only be considered in special situations (for
example in outbreaks in closed communities during inﬂuenza
seasons) [A1]. In the case of seasonal inﬂuenza outbreaks or
a pandemic situation, the national recommendations should
be followed.
New information [492]. Recommendation not changed.
Evidence Table
Reference Objective Design Evidence
Nordstrom
et al. [492]
Oseltamivir prevents pneumonia,
and decreases the use of antibiotics
in patients with ILD
CCS 3B+
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Are oral mucolytics useful for the prevention of LRTI?
Recommendation:
In patients with bronchiectasis, oral mucolytics should not
be used for prevention of LRTI [B1]. Prescription of oral mu-
colytics through the winter months should be considered for
those who have frequent or prolonged exacerbations, or
those who are repeatedly admitted to hospital with exacer-
bations of COPD and for whom inhaled corticosteroids
(ICS) are not prescribed [B1].
Although it has been shown that oral mucolytics prevent
acute exacerbations in patients with chronic bronchitis (1A+),
it has not been shown that these substances prevent infection
in the general population. However, there is some evidence
that individuals who have frequent or prolonged exacerba-
tions, or those who are repeatedly admitted to hospital with
exacerbations of COPD and for whom inhaled corticoster-
oids (ICS) are not prescribed, may beneﬁt from a prescription
of oral mucolytics through the winter months (1A+).
A third systematic review in a row has shown at least
some effect of oral mucolytics in selected patients (severe
COPD, frequent exacerbations, no ICS) [493].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Poole
et al. [493]
Mucolytics for CB or COPD MA 1A+
Is there evidence that homeopathic substances prevent LRTI?
Recommendation: Homeopathic substances should not be
used as a preventive measure against LRTI [C4].
New information [494–496]. Recommendation not changed.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
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Reference Objective Design Evidence
Douglas
et al. [494]
Vitamin C against common cold MA 1A)
Barrett
et al. [495]
Ecchinacea for common cold RCT 2A)
McElhaney
et al. [496]
Extract of the roots of North American
ginseng (Panax quinquefolium)
RCT 2A+
Heimer
et al. [497]
Vitamin C to prevent common cold MA 1B)
Oral care in nursing homes.
Recommendation: Intensiﬁed oral care in nursing home
residents should be considered as a preventive measure to
reduce the incidence of pneumonia and the risk of death
from pneumonia in these patients [B1].
Since the last version of these recommendations one
meta-analysis and two intervention trials have investigated
the question of intensiﬁed oral care in nursing home patients
in relation to the prevention of LRTI or pneumonia.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Sjogren
et al. [498]
A systematic review of the preventive
effect of oral hygiene on pneumonia and
respiratory tract infection in elderly
people in hospitals and nursing homes
MA 1B+
Awano
et al. [499]
To study the risk of death from pneumonia
in relation to dental status
CCS 4C+
Bassim
et al. [500]
To study the risk of mortality from
pneumonia with oral hygiene care
CCS 3B+
Are there commonly used medications decreasing the risk of
LRTI or CAP? Since the last version of these recommenda-
tions a variety of commonly used drugs has been investi-
gated with regard to their potential to decrease the risk of
LRTI or CAP. These drugs are: inhaled steroids in COPD
patients, and ACE-inhibitors or statins in the general popu-
lation.
Inhaled steroids in COPD patients: Inhaled steroids might
decrease the risk of acute exacerbation in subgroups of
COPD patients, but they do not decrease the risk of LRTI.
In fact they seem to increase the risk of LTRI/CAP in COPD
patients.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review
Reference Objective Design Evidence
Singh
et al. [501]
Randomized controlled trials of any inhaled
corticosteroid vs. a control treatment
for COPD, with at least 24 weeks of
follow-up and reporting of pneumonia
as an adverse event were included
MA 1A+
Almirall
et al. [502]
1336 patients with conﬁrmed CAP were
matched to control subjects by age, sex
and primary centre over 1 year.
Multivariable analysis conﬁrmed inhalation
therapy (particularly containing steroids
and using plastic pear-spacers) as
independent risk factors
CCS 4B+
Ernst
et al. [503]
To study the effect of inhaled
corticosteroids on pneumonia
hospitalization
CCS 4B+
Drummond
et al. [504]
To study the effect of inhaled
corticosteroids on pneumonia mortality
MA 1A+
Sin et al. [505] Pooled patient data from seven clinical
trials of inhaled budesonide for the risk
of pneumonia
MA 1A)
Statin use in the general population and the risk of CAP and
death from CAP: The use of statins and/or ACE inhibitors in
the general population has been investigated with regard to
their potential to decrease the risk of CAP or CAP-related
death.
The use of statins and/or ACE inhibitors might decrease
the risk of CAP or CAP-related death in the general popula-
tion. There are many more data for statins then for ACE
inhibitors.
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review.
Reference Objective Design Evidence
Mortensen
et al. [506]
Effect of current statin use and ACE
inhibitor use on 30-day mortality
of patients hospitalized for pneumonia
CCS 4B+
Chalmers
et al. [507]
To study effects of statin use on mortality in
those admitted to hospital with pneumonia
CCS 3B+
Dublin
et al. [508]
Case-control study of statin use in
pneumonia
CCS 4B)
Schlienger
et al. [509]
Current statin users had a signiﬁcantly
reduced risk of fatal pneumonia
CCS B4+
Thomsen
et al. [510]
To study mortality in pneumonia in current
statin users
CCS 4B+
Tleyjeh
et al. [511]
To study statin use to prevent infection SR 1A+
Recommendations for inﬂuenza vaccination
Should inﬂuenza vaccine be used to prevent LRTI?
Recommendation:
1 Inﬂuenza vaccine should be given yearly to persons at
increased risk of complications due to inﬂuenza [A2].
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Vaccination should be given to immunocompetent adults
belonging to one, or more, of the following categories:
age >65 years, institutionalization, chronic cardiac dis-
eases, chronic pulmonary diseases, diabetes mellitus,
chronic renal diseases, haemoglobinopathies, and women
who will be in the second or third trimester of preg-
nancy during the inﬂuenza season [6].
2 Repeated vaccinations are safe and do not lead to a
decreased immune response [B1].
3 In adults, inactivated, rather than live attenuated, vaccine
should be used [A1].
4 Yearly vaccination should be carried out for health care
personnel, especially in settings where elderly persons or
other high-risk groups are treated [B2].
5 General vaccination of all healthy adults should not be
carried out in the absence of robust cost-effectiveness
data for vaccination [B1]
In the elderly (>65 years of age) and in high-risk adults, irre-
spective of age, new studies have conﬁrmed that seasonal
inﬂuenza vaccination is effective in prevention of severe com-
plications or death due to inﬂuenza [512–515]. As most of
these results are based on non-controlled studies, they may
result in either a too pessimistic or too optimistic view of the
effectiveness of vaccination. The latter, based on ‘healthy user
biases’, has been shown in several recent studies [515–518].
A recent Cochrane analysis was unable to reach clear con-
clusions about the effects of the inﬂuenza vaccine in the elderly
[519], but it must be emphasized that a lack of evidence does
not equal a lack of effectiveness. So far, there is unfortunately
only one randomized controlled study of high quality [520].
This study clearly demonstrated that the vaccine was effective
in prevention of clinical and laboratory veriﬁed inﬂuenza in the
elderly, but was not powered to detect effects on complica-
tions. However, based on that study it is reasonable to assume
that the vaccine will also prevent severe inﬂuenza and its
complications, which is in accordance with the ﬁndings of a
large majority of well-performed observational studies.
The speciﬁc age-limit of ‡65 years of age for recommen-
dation of general seasonal inﬂuenza vaccination used in these
guidelines is based on the fact that most trials have used this
cut-off for the inclusion of patients and/or the analysis of the
results. In some countries general vaccination is
recommended also for some age groups below 65 years (e.g.
in the USA, where vaccination is recommended for all per-
sons aged 50–64 years because persons in this age group
have an increased prevalence of high-risk conditions and low
vaccination rates) [521].
Yearly vaccinations with the seasonal inﬂuenza vaccine do
not lead to a decreasing immune response or protection, or
to more frequent effects than those seen after primary vacci-
nation. Two new studies have conﬁrmed that the inactivated
injectable inﬂuenza vaccine is superior to the live attenuated
vaccine in healthy adults [522,523] However, although the
seasonal inﬂuenza vaccine prevents respiratory illnesses in
healthy adults [523,524], a revision of the Cochrane analysis
by Demicheli et al. [525] indicates that vaccination is of only
limited clinical value in this group of patients.
Systematic reviews indicate that vaccination of health care
personnel against inﬂuenza may reduce inﬂuenza-like illness
and all-cause mortality of elderly people in long-term
hospitals, but have not demonstrated an effect on speciﬁc
outcomes, such as laboratory-proven inﬂuenza, pneumonia
or deaths from pneumonia [526,527].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review.
Refernece Objective
Study
design
Evidence
level
Demicheli
et al. [525]
To study the effectiveness of inﬂuenza
vaccination in persons 14–64
years of age
SR 1A+
Hak et al. [512] To study the effectiveness of inﬂuenza
vaccination in adult and elderly
high-risk persons
CCS 4A+
Hak
et al. [513] [2]
To study the effectiveness of inﬂuenza
vaccination in adults 18–64
with COPD
CCS 4A+
Jackson
et al. [516]
To study the effectiveness of inﬂuenza
vaccination in elderly persons
RCS 4A+
Thomas
et al. [526]
To study the effectiveness of inﬂuenza
vaccination of health-care workers in
order to protect elderly persons
SR 1A)
Squarcione
et al. [528]
To study the immunogenicity and
reactogenicity of inactivated inﬂuenza
vaccine in older persons
RCT 2C)
Wang
et al. [522]
To study live attenuated vs. inactivated
inﬂuenza vaccines and medical encounters
for respiratory illnesses among US
military personnel
PCS 3B+
Monto
et al. [523]
Comparative efﬁcacy of inactivated and live
attenuated inﬂuenza vaccines in healthy
adults
RCT 2A+
Nichol
et al. [524]
To study the effectiveness of inﬂuenza
vaccination in prevention of inﬂuenza-like
illness
PCS 3B+
Schembri
et al. [514]
To study the effectiveness of inﬂuenza
vaccination in prevention of all-cause
mortality in elderly persons
RCS 4A+
O¨rtqvist
et al. [515]
To study the effectiveness of inﬂuenza
vaccination in prevention of all-cause
mortality in elderly persons
PCS 3A+
Eurich
et al. [517]
To study the effectiveness of inﬂuenza
vaccination in prevention of all-cause
mortality in elderly persons
PCS 3A+
Jackson
et al. [518]
To study the effectiveness of inﬂuenza
vaccination in prevention of community-
acquired pneumonia in immunocompetent
elderly people
CCS 4A+
Jefferson
et al. [519]
To study vaccines for preventing inﬂuenza in
the elderly
SR 1B)
Thomas
et al. [527]
To study the effect of inﬂuenza vaccination
for healthcare workers who work with
the elderly
SR 1B)
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Recommendations for pneumococcal vaccination
Should pneumococcal vaccine be used to prevent LRTI?
Recommendation:
1 The 23-valent polysaccharide pneumococcal vaccine pre-
vents invasive pneumococcal disease in older persons
and in other high-risk groups and should be given to all
adult persons at risk of pneumococcal disease [A1].
2 Risk factors for pneumococcal disease are: age >65 years,
institutionalization, dementia, seizure disorders, conges-
tive heart failure, cerebrovascular disease, chronic
obstructive pulmonary disease, history of a previous
pneumonia, chronic liver disease, diabetes mellitus, func-
tional or anatomical asplenia, and chronic cerebrospinal
ﬂuid leakage [B3]. Although smoking seems to be a signif-
icant risk factor in otherwise healthy younger adults,
measures aimed at reducing smoking and exposure to
environmental tobacco smoke should be preferred in this
group.
3 Revaccination, once, and not earlier than 5 years after
primary vaccination, should be performed in asplenic
patients and can be considered in the elderly and other
high-risk groups [B3].
4 There are not enough data to give any recommendations
concerning the use of conjugate pneumococcal vaccine in
adults.
The immunogenicity of the 23-valent polysaccharide pneumo-
coccal vaccine (PPV) is generally good, but may be poor in
some elderly patients or in persons with some underlying ill-
nesses (e.g. bronchiectasis) [529]. It is also important to
stress that the PPV includes 23 antigens and that a person
can develop a pneumococcal disease from one of these
serotypes, despite responding to all the others [530]. Previ-
ously, there have been conﬂicting data concerning whether a
pneumococcal conjugate vaccine (PCV) could result in a
superior immune response in elderly patients or high-risk
adults, compared with PPV [531], but a couple of recent
studies do indicate that this may be the case [532,533]. The
drawbacks of PCV, however, are the limited number of sero-
types, the much higher price, and the lack of data on efﬁcacy
(although a large RCT is underway).
Vaccination of children with PCV may be of beneﬁt also
for adults. Since the start of vaccination of children with
PCV in the USA in 2000 a marked reduction of IPD has been
noted both in the vaccinated cohorts and in adults [534,535].
This ‘herd immunity’ effect has been most marked in the age
groups of parents (20–39 years of age) and grandparents
(above 65 years of age). Concerning other outcomes, the
herd effect is less clear, with one study indicating a decrease
of all-cause pneumonia and pneumococcal pneumonia in
adults 18–39 years of age [536], while another showed no
impact at all for all-cause pneumonia in adults [537].
The efﬁcacy of PPV in adults, including the elderly, has
been evaluated in eight meta-analyses/systematic reviews
(MA/SR) of randomized controlled trials (RCTs). The three
most recent reviews have also included a systematic review
of observational studies of invasive pneumococcal disease
(IPD) [538–541]. During the last 2 years, one double-blind
randomized controlled trial and some other studies on the
effectiveness of PPV have been published [542–550].
The MA/SRs of RCTs have shown strong evidence of PPV
efﬁcacy in prevention of invasive pneumococcal disease (IPD)
in healthy adults, including the elderly (40–75% protective efﬁ-
cacy), while the effect against IPD may be somewhat poorer in
persons with chronic illnesses. The estimates of protection
against IPD from SRs of observational studies have been con-
sistent, homogenous and compatible with those of RCTs
[538–541]. Reports of signiﬁcant reductions in the incidence
of IPD in the elderly after the introduction of large-scale vacci-
nation programmes from two European countries support the
effectiveness of the vaccine against IPD [551,552].
There is very limited evidence that PPV prevents all-cause
pneumonia in the elderly or in other risk groups. However,
a recent double-blind randomized controlled trial among
about 1000 nursing home residents in Japan demonstrated
that PPV was associated with a reduction of the incidence of
all-cause pneumonia by 45% and of pneumococcal pneumonia
by 64% [546]. There was also a signiﬁcant higher death rate
among persons with pneumococcal pneumonia in the pla-
cebo group, 35% (13/37) vs. 0% (0/14). This study supports
earlier ﬁndings from recent cohort studies indicating that
PPV is associated with a reduction of pneumonia overall,
pneumococcal pneumonia, hospitalization for pneumonia and
death due to pneumonia [544,545,547,553,554]. In contrast,
some other cohort studies have found no protection against
all-cause pneumonia or hospitalization for pneumonia
[543,550].
In an open RCT, performed in adults with COPD, a high
degree of protection against CAP due to S. pneumoniae or
unknown aetiology was seen in persons <65 years of age,
and especially in those with severe functional obstruction
(FEV1 < 40%) [542]. In contrast, pneumococcal vaccination
did not alter signiﬁcantly the risk of overall CAP in a cohort
study of older adults with chronic respiratory diseases [548].
In European studies, vaccination with PPV of the elderly has
not been cost-saving, but shown moderate to good cost-effec-
tiveness in preventing hospital admission for IPD [555,556].
The most recent study [556] indicated that pneumoccoocal
vaccination would be cost neutral if it was 75–89% efﬁcacious
against IPD or 28–38% against pneumococcal pneumonia in
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the elderly. If the vaccine efﬁcacy against IPD was 50% the net
cost for society would be £2500 per year of life saved. Using
data on the effect of herd immunity from the USA, it has been
estimated that it would be cost-effective from an adult point
of view to vaccinate children in the UK with four doses of the
seven-valent conjugate vaccine [557].
The safety and immunogenicity of one revaccination with
pneumococcal vaccine has been conﬁrmed by several studies
[558–560]. In a large randomized controlled trial patients
who previously had received one dose of PPV were random-
ized to receive PPV or PCV, in four different dosages [558].
Local side-effects were common, but usually mild. The
frequency of local reactions in the PCV group depended on
the dose given, and in the highest dosage group the risk of a
reaction was comparable to that of PPV. In a prospective
cohort study of 61 elderly persons (median age 75 years)
revaccinated on average 5.3 years after the primary vaccina-
tion, signiﬁcant increases of the geometric mean antibody
concentration and geometric mean antibody fold increase
were seen, although to lower levels than after primary vacci-
nation [559]. Thirty-six of 61 (59%) of patients responded
with a fold increase >2, to two or more of six serotypes.
Early revaccination may lead to a short-lived antibody rise,
which could be due to an immunological suppression or
tolerance [532]. However, this suppressive effect seems to
wane after some years and in studies where revaccination
has been performed after 5 years or more persons have
responded well [559,560].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review.
Reference Objective
Study
design
Evidence
level
Van Kessel
et al. [529]
To study immunogenicity of PPV
in patients with bronchiectasis
PCS 3C)
Abraham-Van
Parijs et al. [531]
To compare immunogenicity of PPV and
PCV in healthy and high-risk adults
SR 1B)
Kyaw et al. [534] To study the effectiveness of
reducing IPD in adults by vaccination
of children with conjugate
pneumococcal vaccine
RCS 4C+
Whitney
et al. [535]
To study the effectiveness of reducing
IPD in adults by vaccination of
children with conjugate
pneumococcal vaccine
RCS 4C+
Melegaro and
Edmunds [538]
To study the efﬁcacy of PPV in
adults above 50 years of age
SR 1A)
Dear
et al. [539]
To study the efﬁcacy of PPV
in adults
SR 1A)
Conaty
et al. [540]
To study the efﬁcacy of PPV in adults SR 1A)
Alfageme
et al. [542]
To study the efﬁcacy of PPV in adults
with COPD
RCT 2C+
Jackson
et al. [543]
To study the efﬁcacy of PPV in adults
above 65 years of age
RCS 4B+
Christenson
et al. [544]
To study the efﬁcacy of PPV in adults
above 65 years of age
PCS 3B+
Vila-Co´rcoles
et al. [545]
To study the efﬁcacy of PPV in adults
above 65 years of age
PCS 3B+
Fisman
et al. [553]
To study the efﬁcacy of PPV in adults RCS 4C+
Mykietiuk
et al. [554]
To study the efﬁcacy of PPV in adults PCS 3C+
Melegaro
et al. [555]
To study cost-effectiveness of PPV in
elderly persons
RCS 5B+
Mangtani
et al. [556]
To study cost-effectiveness of PPV in
elderly persons
RCS 5B+
McIntosh
et al. [557]
To study cost-effectiveness in adults
after vaccination of children with PCV
RCS 5B+
Jackson
et al. [558]
To compare safety of PPV and PCV
in elderly persons
RCT 2A+
To¨rling
et al. [559]
To study the immune response to
revaccination with PPV in elderly
persons
PCS 3A+
Sisk [26] To study cost-effectiveness of PPV in
adults 50–54 years of age
RCS 5B+
Andrews [27] To study the efﬁcacy of PPV in adults
above 65 years of age
PCS 4C+
Pepper [28] To study cost-effectiveness of PPV in
healthy adults
RCS 5B+
Ortqvist
et al. [530]
To study response to speciﬁc serotypes
causing failure of 23-valent
pneumococcal polysaccharide vaccine
in the elderly
CCS 4A+
Musher
et al. [532]
To study the initial and subsequent
response to pneumococcal
polysaccharide and protein-conjugate
vaccines administered sequentially to
adults who have recovered from
pneumococcal pneumonia
PCS 3B+
de Roux
et al. [533]
To compare pneumococcal conjugate
polysaccharide and free polysaccharide
vaccines in elderly adults
RCT 2B+
Grijalva
et al. [536]
To study pneumonia admissions after
routine childhood immunization with
pneumococcal conjugate vaccine in
the USA
RCS 4B+
Nelson
et al. [537]
To study impact of the introduction
of pneumococcal conjugate vaccine
on rates of community-acquired
pneumonia in children
and adults
RCS 4A+
Moberley
et al. [541]
Systematic review of vaccines for
preventing pneumococcal infection
in adults
SR 1A+
Maruyama
et al. [546]
To study the efﬁcacy of 23-valent
pneumococcal vaccine in preventing
pneumonia and improving survival in
nursing home residents
RCT 2A+
Christenson
et al. [547]
To study the effect of inﬂuenza and
pneumococcal vaccines in elderly
people
PCS 3C+
Ochoa-Gondar
et al. [548]
To study the effectiveness of
pneumococcal vaccination in older
adults with chronic respiratory diseases
PCS 3B)
Lee
et al. [549]
To study the impact of pneumococcal
vaccination on pneumonia rates in
adult patients with COPD and asthma
RCS 4B+
Skull
et al. [550]
To study whether inﬂuenza and/or
pneumococcal vaccine prevents
hospitalization because of community-
acquired pneumonia in the elderly
CCS 4B)
Johnstone
et al. [561]
To study the effect of pneumococcal
vaccination in hospitalized adults with
community-acquired pneumonia
PCS 3B+
Waites
et al. [560]
To study the effects of revaccination
of adults with spinal cord injury using
the 23-valent pneumococcal
polysaccharide vaccine
PCS 3A+
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Recommendations for implementation.
Recommendation: Active interventions should be used to
enhance vaccination with either, or both, of the vaccines and
is effective and needed to in order to achieve an adequate
vaccination coverage of the targeted population [A1].
New studies have conﬁrmed that different types of
interventions (e.g. patient reminders or standing orders) are
effective for increasing vaccination of the targeted population
against inﬂuenza and pneumococcal disease [562–565].
Evidence Table
MA, meta-analysis (or systematic review); RCT, random-
ized controlled trial; PCS, prospective cohort study; RCS,
retrospective cohort study; CCS, case-control study; CSS,
cross-sectional study; SR, systematic review.
Reference Objective
Study
design
Evidence
level
Dexter
et al. [562]
To study the effectiveness of different
methods to increase vaccine coverage
in adults eligible for vaccination
RCT 2C+
Jacobson
et al. [563]
To study the effectiveness of different
methods to increase vaccine coverage
in adults of all age groups
SR 1A+
de Hart
et al. [564]
To study the effectiveness of different
methods to increase vaccine coverage
in elderly persons
PCS 3C+
Jha et al. [565] To study performance measures,
vaccinations and pneumonia rates
among high-risk patients in Veterans
Administration health care
RCS 4C+
Appendix 1
Evidence grades (hierarchy of methods)
1. = Systematic reviews and meta-analyses (of study types
under grade 2 or 3)
2. = Randomized trials
3. = Prospective cohort
4. = Case-control, cross-sectional, retrospective cohort
5. = Case reports
6. = Expert opinion, consensus
Sufﬁx for evidence grades 1–6.A = low risk of biased results
(ﬂaws very unlikely for both blinding and follow-up)
B = moderate risk of biased results (ﬂaws unlikely for both
blinding and follow-up)
C = high risk of biased results (ﬂaws likely for either or both
blinding and follow-up)
Sufﬁx for evidence grades 1A–6C.+ = determinant-outcome
relation of interest clearly established
i.e. the numerical results from the study unequivocally
support a positive answer to the research question
) = determinant-outcome relation of interest clearly not
established
i.e. the numerical results from the study are unequivocally
not supportive of a positive answer to the research question
? = determinant-outcome relation of interest unclear
Appendix 2
Recommendation grading
Grades
A = Consistent evidence ->Clear outcome
B = Inconsistent evidence ->Unclear outcome
C = Insufﬁcient evidence ->Consensus
Sufﬁx for recommendation grades A–C
For studies of diagnosis and treatment (including prevention
and harm)
1. = Systematic review (SR) or meta-analysis (MA) of RCTs
2. = 1 RCT or more (>1: no SR or MA yet)
3. = 1 cohort study or more (>1: no SR or MA yet)
4. = Else
For studies of prognosis and aetiology
1. = SR or MA of cohort studies
2. = 1 cohort study or more (>1: no SR or MA yet)
3. = Else
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